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SUMMARY
In our previous study, we identified a novel gene in mouse that was capable of
reversing the acquired drug resistance in murine tumor cells against a panel of anticancer
drugs including etoposide, vincristine, cisplatin and tamoxifen. Interestingly, BLAST
search revealed a 60% homology between the novel mouse gene and a human gene,
mitogen-inducible gene-2 (mig-2). This finding raised an intriguing question: whether or
not mig-2 could exhibit similar function, i.e. reversing drug resistance, in human cancer
cells. Mig-2 was identified in 1994 as an immediate early gene in mitogen-mediated
signal transduction in human fibroblasts cells WI-38. To date its biological functions,
however, remain poorly understood.
Two recent publications disclosed some investigations on mig-2. In one study, mig-2
was found to be one of the components in cell extracellular matrix adhesion complex,
participating in cell shape modulation. In the other study, two novel mig-2 homologous
genes were identified. One was found overexpressed in human lung and colon
carcinomas whereas the other was found silenced in patients with Kindler syndrome, an
autosomal recessive skin disorder. These studies, together with its identification process,
further aroused the question on mig-2 gene function. We therefore initiated a pilot study
aiming to explore the functional significance of mig-2. Our hypothesis was that mig-2
might enhance cancer cell susceptibility against anticancer drugs. The study aimed to test
our hypothesis by exploring the potential functions of gene mig-2 in human cancer cells.
The human colon cancer HT-29 cell line, a mig-2-null cell line as examined
experimentally, was chosen for transfection studies to investigate mig-2 gene function.
viii
Our data showed that re-expression of mig-2 in HT29 cells exerted antiproliferative
effects and induced apoptosis. The growth inhibitory effect of mig-2 was confirmed by
colony formation and cell growth assay. Mig-2 mediated apoptosis was determined by
flow cytometry and TUNEL assay. However, MTT assay failed to demonstrate any
significant enhancement of the killing effect of anticancer drugs on HT29 cells
transfected with mig-2. Furthermore, mig-2-GFP fusion protein revealed that mig-2 was
predominantly localized in the cytoplasm of both HT29 and MCF-7 cells. The expression
of endogenous mig-2 was serum-dependent.
In conclusion, mig-2 gene may play an important role in the regulation of human cell
proliferation; however the underlying mechanism is yet studied.
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1CHAPTER1        INTRODUCTION AND LITERATURE REVIEW
1.1 Overview of mig-2
1.1.1 Identification of mig-2
Mitogen inducible gene-2 (mig-2) was initially identified in human diploid fibroblasts
cell line WI-38 (Wick et al., 1994). The WI-38 cells were starved in serum free medium
for 72 hours (h) to establish quiescent cells system. The quiescent cells were stimulated
when adding serum back into the culture medium. Differential cDNA library screening
was performed to identify serum inducible genes during G0S progression. Besides 11
known genes found, 4 novel genes were identified in their study, which were designated
as mig-1, mig-2, mig-3 and mig-4 respectively. Interestingly, one of the novel genes,
mig-2, was reported possessing a 60% homology with an open reading frame (ORF) in
the non-coding strand of the human transcription factor HTF-4 (Zhang et al., 1991), a
helix-loop-helix transcription factor. This finding raised intriguing questions on mig-2
gene. The biological functions of mig-2 gene, however, have remained unknown since its
identification.
1.1.2 IE Gene
1.1.2.1 Classification of mitogen inducible genes
The expression of mitogen inducible genes is induced in a cell cycle-dependent
manner. These genes express in a limited manner in quiescent cells, however when
quiescent cells are induced to reenter the cell cycle by addition of appropriate mitogenic
stimuli, the products of mitogen inducible genes (mRNA and/or proteins) accumulate in
cytoplasm at various times as the cells progress through the cell cycle.
2The mitogen inducible genes are divided into 3 different categories: Immediately early
(IE) primary genes, delayed early (DE) secondary genes and late genes.
A) IE genes are defined by three criteria: 1. Their transcripts, which are at low or
undetectable levels in quiescent cells, rapidly accumulate to detectable levels within one
hour of growth-factor stimulation. 2. Their expression is independent of de novo protein
synthesis. 3. Their transcriptional activation is mediated by growth-factor stimulation.
According to these criteria, more than 60 IE genes have been identified in 3T3 fibroblasts
(Lim et al., 1989). Many IE genes are encoding transcription factors such as c-Fos, c-Jun,
NF-κB, etc.
B) DE genes are expressed approximately 3-8 h after mitogen stimulation and
before the onset of DNA synthesis. Many of these DE genes require de novo protein
synthesis for their expression, suggesting that they are regulated by IE genes. However, at
present there are few known examples of DE genes that are direct targets of specific IE
genes. Although a number of DE genes have been identified, undoubtedly many others
are yet to be described.
C) Expression of late genes reaches peak level during S phase. It has been shown
that in normal cell cycle progression the late genes are subjected to a clear cell cycle
regulation.
1.1.2.2  Some critical proteins encoded by IE genes
Characterization of the proteins encoded by IE genes is crucial for understanding the
genetic program activated by growth factors. The hypothesis that IE proteins mediate the
downstream cellular responses to growth factors has been supported by the discovery that
a number of them are known or likely transcription factors, oncoproteins, and cytokines.
3Moreover, expression of antisense RNAs, in some cases, results in inhibition of cell
proliferation (Heikkila et al., 1987, Holt et al., 1988).
The following list a few critical and intensive characterized proteins encoded by IE
genes, which could shed some light on the functional exploration on the uncharacterized
IE genes like mig-2.
A) Fos and Jun Family Members: considerable exciting findings have surrounded
the Fos and Jun protooncogenes, particularly since the discovery that they encode
proteins that can form heterodimers and constitute the major components in the
transcription factor AP-1 (Vogt and Bos, 1990). C-Fos is one of the first protooncogenes
that is rapidly activated by growth factors (Müller et al., 1984). Most of other Fos-related
proteins are encoded by IE genes as well, including Fos B (Zerial et al., 1989), Fos-
related antigen 1 (Fra-1; Cohen and Curan, 1988), and Fra-2 (Nishina et al., 1990). Both
c-Jun and a related gene, Jun B are IE genes. Another member of the Jun family, Jun D,
is expressed continuously and is not inducible by growth factors (Hirai et al., 1989).
B) Rel and NF-κB: the protooncogene rel is an IE gene activated by serum (Bull
et al., 1989), and its product can function in regulating transcription (Bull et al., 1990).
Rel is homologous to the DNA-binding subunit (p50) of NF-κB (Ghosh et al., 1990), a
transcription factor that binds the NF-κB site in the immunoglobulin enhancer (Lenardo
and Baltimore, 1989). NF-κB plays a significant role in the inducible expression of a
large number of genes, including cytokines, cytokines receptors, major histocompatibility
antigens, and genes in a number of viruses.
C) Myc: the c-Myc protooncogene is among the first genes to be recognized as an
IE gene (Kelly et al., 1983). Overexpression of c-Myc or microinjection of c-Myc protein
4into 3T3 cells partially alleviates the cell’s requirement for exogenous growth factors for
DNA synthesis (Kaczmarek et al., 1985). Also, Myc antisense oligonucleotides inhibit G1
cells from progressing into S phase (Heikkila et al., 1987; Holt et al., 1988) indicating
that the function of Myc is important for cell growth.
D) Serum-Response Factor: the p67SRF serum-response factor appears to play a
role in the transcriptional activation of c-Fos and a number of other IE genes. The
molecular cloning of p67SRF makes possible the characterization of its pattern of
expression and the discovery that it is encoded by an IE gene (Norman et al., 1988).
p67SRF is a phosphoprotein of 508 amino acids, and it most likely binds DNA as a
dimmer. Its DNA binding domain is homologous to that of the yeast transcription factor
MCM1, which regulates the expression of genes involved in mating and is required for
the maintenance of minichromosomes (Passmore et al., 1989).
1.1.2.3  Mig-2 belongs to IE genes
Wick et al. showed that the induction of mig-2 was independent on the protein
synthesis de novo because mig-2’s expression could be induced in the presence of protein
synthesis inhibitors such as puromycin and emetine. The peak level of expression for
mig-2 was 7-20 fold compared to the expression in quiescent cells. The time for reaching
peak was approximately 4 h. The induction time for mig-2 was less than 8 h (Wick et al.,
1994). According to these findings they concluded that mig-2 belonged to IE genes group
in the mitogen stimulated signal transduction. Considering the complexity and
importance of proteins encoded by IE genes as we described above, its potential
significance needs to be investigated further.
51.2 Potential significance of mig-2 gene --- our hypothesis
Mig-2 gene has remained uncharacterized since its identification in 1994. However, it
shows potential significance in anticancer drug resistance and cell growth control. Based
on our previous data, we made the hypothesis that mitogen inducible gene-2 might
enhance cancer cell susceptibility against anticancer drugs and initiated a pilot study on
mig-2 function.
1.2.1 Possible involvement of mig-2 in anticancer drug resistance
1.2.1.1 Overview of drug resistance in cancer chemotherapy
The term “Chemotherapy” was given by Paul Ehrlich in the early 20th century during
his searching for a chemical that would cure syphilis. In late 1940s, Gillman and his
colleagues treated a patient with lymphosarcoma using nitrogen mustard, whose
anticancer action led to a sharp rise of interest in cancer chemotherapy program and a
large scale of screening program for the discovery of new anticancer drugs. Nowadays,
there are approximately 60 drugs available for the treatment of various types of cancer.
They are derived from a variety of sources and act on many different biochemical
processes within the cells. The majority of them are developed empirically. In recent
years our knowledge of the regulation of growth and death in cancer cells has expanded
enormously. This leads to a better understanding of how these chemotherapeutic agents
work and change the face of drug development.
The success of chemotherapy in the treatment of some malignant diseases was
dramatic. For example, before 1980 the five-year disease-free survival in childhood acute
lymphoblastic leukemia was 39%, by the end of 1990s, this had increased to 63% (Guy
and Caroline, 2001). However, in the common epithelial malignant diseases of adult life
6such as carcinomas of breast, colon, lung and liver, etc., the impact of chemotherapy was
disappointing. The major obstacle to an effective chemotherapy is the development of
resistance to anticancer drugs in cancer cells.
Anticancer drug resistance is defined as a state of insensitivity or decreased sensitivity
of a population of cancer cells to drugs that ordinarily cause cell death. Two types of
resistance have been defined on the basis of the ability of tumor cells to either escape
from drug effects spontaneously (innate resistance) or after a delay (acquired resistance).
The phenomenon of drug resistance was recognized very early in the history of cancer
chemotherapy. About 50 years have passed since the initial publication of this
phenomenon (Burchenal et al., 1950). To date numerous mechanisms of anticancer drug
resistance have been identified and studied using principally human cancer cell lines.  All
of them are associated with one or more levels of the action of a drug in a cell. It is a
general principle that a drug must first be transported into a cell and then may need some
intracellular activation, and finally binds to the target to exert its cell-killing effects.
Recently the downstream regulation of cell death has been studied intensively such as
apoptosis and cell cycle control, which may play a critical role in the drug killing.
1.2.1.2 Genetic factors in anticancer drug resistance
A wide variety of genetic factors have been implicated as determinants of anticancer
drug resistance including oncogenes, tumor suppressor genes, cell cycle checkpoints,
intracellular signaling cascades, mechanisms of apoptosis, etc.  Many mechanisms of
drug resistance are described in which drug-target interaction is modified. These
mechanisms, basically regarded as upstream events, include: transporting drug into cells,
drug activations, interactions between drugs and targets, and finally intervention of cell
7repair processes. However there is at least one step downstream to make the actions of a
drug successful. That is the process of programmed cell death or so-called apoptosis of
cancer cells. It has been demonstrated that most anticancer agents exert their killing
effects by inducing cancer cell to undergo apoptosis. Thus any factor that prevents cells
from apoptosis may confer resistance to the cancer cells against a broad panel of
anticancer drugs. Apoptosis is increasingly recognized as a key mechanism for drug
resistance.
There is considerable evidence that an important early event in apoptosis involves p53
(Greenblatt et al., 1994). P53 protein binds to specific areas on the DNA and functions as
a transcription factor that is capable of initiating a number of complex sequences,
including apoptosis. Studies have shown that the status of p53 correlates with the
sensitivity of cells to undergo apoptosis. Homozygous cells for wild-type p53 are much
more sensitive to a number of different anticancer agents as well as radiation than those
homozygous for mutated or nonfunctional p53 (Lowe et al., 1993 and Xia et al., 1995),
and heterozygous cells for p53 appear to have intermediate-level sensitivity.
P53 is not the only initiator of apoptosis in the cells. Certain oncogenes, for example
c-myc, produce positive signals for cell proliferation and may actually sensitize the cells
to undergo apoptosis at a low level of cell damage (Martin SJ and Green DR, 1995). On
the other hand, many signaling pathways exist between a number of cell-surface
receptors and Bcl-2 family proteins, for example interleukin-3 receptor ligation leads to
the phosphorylation of Bad, which prevents Bad from binding to Bcl-XL thus free Bcl-XL
to block apoptosis (Zha et al, 1996). Within the framework of signaling pathways
8between cell death and survival, there are multiple points at which the activation of
apoptosis can be abrogated and subsequent resistance may occur.
In addition to the relatively well-studied area of apoptosis, a number of other modes of
cell death have been characterized. These include mitotic catastrophe which is associated
with damage to the mitotic spindle, occurs at the G2/M checkpoint, and may have special
relevance to the action of spindle poison such as the taxanes and vinca alkaloids (Sané et
al., 1999 and Dumontet et al., 1999). Another important mechanism is necrosis, which
differs from apoptosis in a number of ways: for example apoptosis is the controlled auto-
digestion by activation of endogenous proteases resulting in cell shrinkage, membrane
blebbing and nuclear condensation, whereas necrosis is an acute inflammatory and
pathological cell death typified by cell swelling and lysis. Many variants of typical
apoptosis are described as well, which can occur if the caspase system is impaired or
nonfunctional. It suffices to say that the study of various death programs will have
enormous impact on our understanding of resistant state as well as how various
anticancer drugs act.
1.2.1.3  Identification of a novel gene in mouse
In our previous study, we identified a novel gene in mouse murine lymphoma cell line
EL4. The gene was found to be capable of reversing the acquired drug resistance of the
cells against a series of anticancer drugs including etoposide, vincristine, cisplatin, and
tamoxifen. The P value was less than 0.01 in all cases (Shen, et al., 1999). Interestingly,
BLAST search revealed that this gene shared a high sequence homology (60%) at both
nucleotide and protein level with the human mig-2 gene. This finding led us to ask if
9mig-2 gene was able to enhance the killing effect of anticancer drugs on human cancer
cells.
1.2.1.4  Preliminary study on mig-2
In order to establish our hypothesis on the relationship between mig-2 expression and
cell sensitivity to anticancer drugs, we carried out some preliminary study. Firstly, we
examined the expression level of mig-2 gene in 4 human cancer cell lines including
MCF-7, Colo205, HT29 and HCT116. We observed that mig-2 gene was highly
expressed in MCF-7 and HCT116 but was not expressed in HT29 or Colo205.
Subsequently we investigated the sensitivity of these four cell lines to a series of
commonly used anticancer drugs based on the information provided by the
Developmental Therapeutics program NCI/NIH (DTP). The drugs we chose were
etoposide, 5-Fluorouracil (5-FU), mitomycin C, vincristine and cisplatin. The cytotoxic
effect was represented by the absolute values of logGI50 in Figure 1-1. GI50 is the drug
concentration that causes 50% cell growth inhibition. Our investigation showed that
MCF-7 and HCT116, which expressed mig-2 gene, were more sensitive (higher logGI50
absolute value) to all the chosen drugs except for vincristine than Colo205 and HT29 that
lost mig-2 expression. In each case the P value was less than 0.05.
This preliminary study, together with the homology between mig-2 and the novel gene
identified in mouse, strongly supported our hypothesis on the possible role of mig-2 in
anticancer drug resistance.
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FIGURE1-1 Sensitivity against different drugs in 4 cell lines. A) One-Step RT-PCR
showing the expression status of mig-2 in the 4 cell lines. B) The absolute value of
logGI50 of anticancer drugs against these 4 cell lines, representing cell susceptibility to




1.2.2 Possible role of mig-2 in cell growth control
1.2.2.1 Overview of cell cycle and growth control
The mammalian cell cycle is the focus of a large number of studies at both genetic and
molecular level. The cell cycle can be described as the period between the formation of
the daughter cell, by division of a mother cell, and the subsequent time in which the cell
divides to form two more daughter cells (Mitchison, 1971). This period was initially
divided into two parts called interphase and mitosis. With the advent of radiographic and
cytophotometric techniques, interphase was further divided into four phases. The
pioneering studies of Howard and Pelc in 1951 were the first to use radiographic to
determine when DNA was being actively synthesized (Howard and Pelc, 1951, 1953).
These studies, along with additional microscopic observations, provided a means to
introduce the concept of the cell cycle. They divided the cycle into four stages: (1) the
presynthetic gap or gap1 (G1); (2) DNA synthesis (S phase), the time of bulk
incorporation of radio-labeled DNA precursor and subsequent DNA replication; (3) the
post-synthetic gap or gap 2(G2), the interval between the end of S and the initiation of
mitosis; and (4) mitosis, the period during which the chromosomes condense, and
cytokinesis is completed (Howard and Pelc, 1953).
The cell cycle described above was accepted for those cells that were actively
dividing. However, it soon became obvious that in an adult animal, not all cells were
actively dividing at all time. Thus a further modification was introduced into this system.
With the addition of those non-dividing cells, the diagram of the mammalian cell cycle
had to be modified to take into account the fact that some cells continually divide, others
leave the cycle but remain the ability to reenter it, and still others leave and never
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proliferate again (Wier and Scott, 1986). Thus the modified model of cell cycle included
actively proliferating cells, which cycle through G1, S, G2 and M; non-dividing cells or
terminally differentiated (TD) cells and the non-dividing or quiescent (G0) cells.
1.2.2.2 Mig-2 involved in mitogenic signaling cell cycle control
Because mig-2 was identified in the progression of G0S phase upon serum
stimulation (Wick et al, 1994), it was regarded as a gene involved in the mitogen-
mediated cell cycle regulation and possibly stimulating cells to proliferate. It was noted
that most of anticancer drugs were primarily effective against rapidly dividing cells
(Tomida and Tsuruo, 1999), which further supported our hypothesis that mig-2 might
enhance the cell sensitivity in cancer chemotherapy.
To initiate the mitogenic response, growth factors interact with, and consequently
activate, specific membrane-bound receptors. Receptor activation, in turn, stimulates the
formation of various signaling molecules, which transfers the mitogenic signal from cell
membrane to the internal part. Regarding the cell cycle regulation, it is known that
mitogenic signaling by growth factors activates the Ras-Raf-MEK-ERK signal
transduction cascade (Schaeffer and Weber, 1999). Ras proteins are located at the inner
face of the plasma membrane where they serve as relay switches to transmit extracellular
signal-mediated stimuli to cytoplasmic signaling cascades (Boguski and McCormick,
1993). Ras proteins function as GDP/GTP-regulated switches that cycle between an
active GTP-bound state and an inactive GDP-bound state. Mitogenic signals stimulate a
transient formation of active GTP-bound Ras and activated Ras in turn interacts with
downstream effector targets. The intensively characterized Ras effectors are the Raf
serine/threonine kinases (Campbell et al., 1998; Shields et al., 2000). Activated Raf
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activates the MEK dual specificity kinases, which subsequently activate the extracellular
regulated kinase (ERK). The ERK signaling critically determines the biological response
of the cells because ERK activation plays a crucial role in cyclin D1 induction (Lavoie et
al., 1996).
Cyclin D1 is induced transcriptionally in response of mitogenic stimulation
(Matsushime et al., 1991). Transcription and protein expression of cyclin D1 are typically
elevated in mid-G1, associated with the second peak of Ras activation (Gille and
Downward, 1999), with maximal accumulation occurring close to the G1/S transition.
Serum-stimulated up-regulation of cyclin D1 expression is dependent upon Ras function
and constitutive expression of cyclin D1 can overcome the requirement of Ras in
proliferation of NIH 3T3 cells (Aktas et al., 1997).
The importance of the Ras-Raf-MEK-ERK pathway in the regulation of cyclin D1 is
undisputed, but some other studies also highlight the requirement of other pathways for
the induction of cyclin D1. It was found that the second peak of serum-stimulated
activation of Ras corresponded to activation of Akt, a target of phosphoinositide-3-OH
kinase (PI3K, Gille and Downward, 1999). Cyclin D1 expression was also found
dependent on PI3K activity. This observation, together with the ability of the Akt to
cause up-regulation of cyclin D1, indicated that Ras activation of PI3K also contributed
to the up-regulation of cyclin D1.
As an uncharacterized gene, mig-2 has little information available. However we found
the evidence that mig-2 was included in the gene list of cell cycle control provided by
GeneServer, which is an integrated database of genes, gene products and their
involvement in diseases. Some of the cell cycle control genes in the GeneServer are listed
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in Table 1-1. The functions of these genes may associate with cell cycle control or cell
proliferation. But there is no information on the mig-2 protein or other related factors
demonstrated in the list, indicating that mig-2 gene is still uncharacterized.
TABLE1-1 Some of the cell cycle control genes in the GeneSever
 Gene                                          Name                                                  Sequence ID
   _ _  _
 MCM5 minichromosome maintenance deficient NM_006739
 (S. cerevisiae) 5 (cell division cycle 46)
 MCRS1 microspherule protein 1 NM_006337
 MCT-1 MCT-1 protein NM_014060
 MIG2 mitogen inducible gene-2 Z_24725
 MKI67 antigen identified by monoclonal antibody Ki-67 NM_002417
 MNT MAX binding protein NM_020310
 MOS v-mos Moloney murine sarcoma NM_005372
 viral oncogene homolog
   _ _  _
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1.3 Recent studies on mig-2
Recently several studies on mig-2 gene have been published. Clearly increasing
interest is drawn onto this uncharacterized gene. However none of them demonstrated the
involvement of mig-2 gene in drug resistance or cell growth control.
1.3.1 Mig-2 gene involved in cell adhesion
Tu et al. found that mig-2 protein, as a component of the cell extracellular matrix
(ECM) adhesion structure, functioned in cell shape modulation in human fibroblast cells
WI-38 and mouse C2C12 cells (Tu et al., 2003). This finding was consistent with the
studies on UNC-112, the C. elegans ortholog of mig-2. UNC-112 was identified in year
2000 and has been well characterized (Rogalski et al., 2000). It is a membrane-associated
intracellular protein that co-localizes with β-integrin in adhesion complexes. It binds to
integrin to promote cross-linking of the actin cytoskeleton and formation of dense bodies
(Schaller, 2000). UNC-112 is recently identified as a new binding partner for integrin-
linked kinase (ILK), which is also an adaptor within integrin-associated cytoskeletal
complexes implicated in integrin-mediated signaling (Mackinnon et al., 2002). ILK is
considered as the major survival determinant in the integrin pathway (Dedhar, 2000). As
a serine/threonine kinase, ILK plays a critical role in cell proliferation, cell survival, and
tumor formation (Dedhar, 2000; Persad et al., 2000).
In contrast to UNC-112, information pertaining to the functions of mig-2 in human
cells is extremely limited. Tu et al. recently showed that mig-2 was involved in cell shape
modulation through the recruitment of migfilin to cell-matrix adhesions and the
interaction with filamin. Consistent with the studies in C. elegans, mig-2 was also
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predicted to be physically and functionally coupled to ILK and consequently integrins in
mammalian cells (Tu et al., 2003).
1.3.2 Integrin signaling pathway in cell growth control
Integrins are cell surface receptors connecting cells to the surrounding ECM. They not
only support cell attachment but also act in many other physiological and pathological
processes regarding cell survival, differentiation and proliferation. All integrins are
heterodimers consisted of two subunits, α and β. Each integrin molecule is composed of
a large extracellular ligand-binding domain, containing portions of both α- and β-
subunits, a single transmembrane domain, and a small cytoplasmic domain (Hynes,
1992). Unlike other transmembrane receptors, the cytoplasmic portion of integrins has no
detectable enzymatic activity. Thus integrins are believed to mediate all their signaling
effects by recruiting and activating different intracellular signaling and adaptor proteins.
ECM binding initiates clustering of integrins in the plane of the membrane and
reorganization of the actin cytoskeleton, which further stimulates the organization of
integrins and associated proteins into large multi-protein aggregates termed cell-matrix
adhesions (Burridge and Chrzanowska-wodnicka, 1996; Yamada and Geiger, 1997).
These structures contain many signaling proteins acting as signaling units.
Regulation of the cell growth by integrin signaling i.e. cell adhesion is restricted in G1
phase and G1/S transition with cooperation of mitogen stimuli. As we know, progressions
through G1 and G1/S transition are controlled directly by different transcription
mechanisms including: (1) the E2F family of transcription factors, (2) the Rb tumor
suppressor family, and (3) chromatin remodeling enzymes (Harbour and Dean, 2000). In
the presence of mitogens, the accumulation of cyclin-dependent kinase (cdk) activities
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progressively increases Rb phosphorylation, which in turn results in a gradual releasing
of E2F, cyclin E and cyclin A. This positive feedback loop will continue until the
phosphorylation of Rb is completed and cdk activity starts to inhibit E2F function. At this
time, cells have passed G1/S transition and are committed to complete the whole cell
cycle (Pardee, 1989).
G1 progression depends on the sustained expression and accumulation of cyclin D
(Ekholm and Reed, 2000). Integrin-mediated cell adhesion cooperates with mitogens to
control the accumulation of cyclin D (Zhu et al., 1996). The induction of cyclin D
subsequently provides initial phosphorylation of Rb, which is important for re-depression
of the cyclin E gene (Harbour and Dean, 2000). The induction of cyclin D also results in
a redistribution of the p21 and p27 cdk inhibitors (cki) from cyclin E-cdk2 complex to
cycin D-cdk4/6. This allows the cyclin E-cdk2 to further phosphorylate Rb, resulting in
de-repression of the cyclin A gene (Sherr and Roberts, 1999). It has been found that
adherent cells maintained in suspension are lack of Rb hyperphosphorylation in G1 and
fail to induce cyclin A at the onset of S phase (Fang et al., 1996). This finding may be a
mere consequence of the anchorage-dependence of cyclin D expression and cyclin E-
cdk2 activity.
In conclusion, the major mode of cell cycle control by integrin-mediated adhesion is
the induction of cyclin D in early G1 and the suppression of cki in mid G1 phase.
Mitogens and integrin-mediated adhesion remain necessary throughout G1 phase.
Through the initial Rb phosphorylation and redistribution of cki, it ensures the
accumulation of active cyclin E-cdk2 in late G1, which in turn further phosphorylates Rb,
leading to the induction of cyclin A at the onset of S phase. Once cells have passed the
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restriction point, completion of the whole cell cycle is neither mitogen-nor anchorage-
dependent.
1.3.3 Apoptosis related to integrin---Anoikis
Apoptosis triggered by loss of cell anchorage is called anoikis. Meredith et al.
(Meredith et al., 1993) found that fibroblasts needed cell anchorage for survival and later
on the term “anoikis”, the state of homelessness in Greek, was chosen to describe this
form of apoptosis (Frisch et al., 1994). The anchorage of cells to components of the ECM
is mediated mainly by integrins (Meredith et al., 1996). The intracellular molecular
mechanisms propagating integrin-mediated signals have been intensively studied over
recent years (Cary and Guan, 1999; Giancotti and Ruoslahti, 1999). Key players in
integrin-mediated signal transduction are a group of kinases, two of them being Focal
Adhesion-Kinase (FAK) and ILK. Upon integrin association FAK is phosphorylated and
interacts with numerous signaling molecules allowing the recruitment of other signaling
elements to the FAK signaling complex. The FAK signaling complex mediates the
activation of several mitotic signaling pathways, such as PI-3K pathway with its
downstream target Protein kinase B (PKB/AKT) (Khwaja et al., 1998), ERK pathway
(Rak et al., 1995; Le Gall et al., 2000) and the Jun-NH2-terminal kinase (JNK)/mitogen
activated protein kinase (MAPK) pathway (Oktay et al., 1999; Almeida et al., 2000).
JNK is crucial in integrin-mediated signal transduction in cell survival. It directly
phosphorylates PKB/AKT, which leads to multiple inhibitory effects on apoptosis such as
inactivation of caspase-9 (Cardone et al., 1998) and Bad protein (Datta et al., 1997),
activation of NF-κB (Datta et al., 2000) and inhibition of Forkhead family transcription
factors (Romashkova et al., 1999; Brunet et al., 2001). Cessation of PKB/AKT signaling
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causes a series of reactions stimulating apoptosis such as translocation of Bad to the
mitochondria, alteration of the Bad/Bcl-2 ratio, pore formation in the mitochondria outer
membrane and releasing of cytochrome c from mitochondria (Kops and Burgering, 2000;
Romashkova et al., 1999).
Perturbation of cell matrix adhesion led by down-regulation of expression and
functional activity of α2 β1 integrin might be a mechanism by which apoptosis occurred
in colorectal cancer cells induced by bytyrate (Buda et al., 2003). Meanwhile serum-
starved HT-29 cells could be protected from apoptosis by overexpression of the α5
subunit of integrin (O’Brien et al., 1996). These studies on integrin-mediated signaling of
apoptosis in colon cancer cell line provide us with clues on the exploration of mig-2
gene’s functions in HT29 cells.
1.3.4 Homologues of mig-2
Weinstein et al. recently identified two novel mig-2 homologues, URP1 and URP2,
and showed that URP1 and mig-2 were most closely related, being 65.5% identical and
74.2% similar to each another (Weinstein et al., 2003). URP1 was overexpressed in
human lung and colon carcinomas, indicating its potential significance in carcinogenesis
and being a marker for cancer diagnosis. Expression of mig-2, conversely, was shown
decreased in colon carcinoma and no significantly changed in other types of human
tumors. Siegel et al, however, identified a novel mig-2 homologue Kindlin-1, which was
down regulated in patients with Kindler syndrome, an autosomal recessive skin disorder.
They therefore defined a family of kindlin-related proteins namely Kindlin-1, Kindlin-2
(mig-2) and Kindlin-3 (Siegel et al., 2003).   
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1.3.5 PH domain and FERM domain
Interestingly, the sequence analysis revealed the similar filopodin and
erin/radixin/moesin (FERM) domain and pleckstrin homology (PH) domain structures in
mig-2 gene and its homologues.  This observation suggested an interesting function of
mig-2, for the FERM domain characteristic of cytoplasmic plasma membrane to
cytoskeleton linkers (Chishi et al., 1998) and the PH domain typical of membrane-
anchored protein involved in signal transduction (Musacchio et al., 1993).
The PH domain consists of two repeats of approximately 100 residues in pleckstrin,
the major substrate for serine/threonine phosphorylation by protein kinase C in platelets
(Haslam et al., 1993; Mayer et al., 1993). The frequently turning up of PH domain in
intracellular signaling and cytoskeletal proteins makes it the focus of great interest. In
fact, the PH domains in mig-2 gene were reported in 1994 (Gibson et al., 1994) when the
new PH domains were used to screen in the EMBL database. Mig-2 protein of unknown
function was demonstrated being a divergent relative of the ezrin/band 4.1 group of
cytoskeletal proteins located at the plasma membrane, but having clear sequence
similarity only to the amino-terminal 400 residues of the multidomain protein talin.
The specific domains contained in mig-2 further indicate its potential significance. It
also provides us with useful information when exploring the functions of mig-2 gene.
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1.4   Strategies to explore mig-2 gene function
Based on our preliminary research, we initiated a pilot study on the functional
significance of mig-2 gene in the fields of anticancer drug resistance and cell growth
control. The following strategies were designed and carried out in this study.
A. Cloning the full-length cDNA of mig-2
The full-length cDNA of mig-2 was generated by PCR from MCF-7 cells in
which mig-2 gene was highly expressed. Briefly, total RNA from cells was extracted for
reverse transcription (RT). The first-strand cDNA was used as the template for PCR to
produce full-length cDNA of mig-2. Once the cDNA was obtained, it was cloned into
different plasmids for various purposes including pGEM-T for cloning and sequencing,
pcDNA3.1 for functional study, and pEGFP-N2 for cellular localization.
B. Re-expression of mig-2 in mig-2-null cell line HT29 to determine its capability
of conferring cell sensitivity to anticancer drugs and to observe the effect of mig-2 on cell
behavior. Both transient and stable transfections were performed to examine the role of
mig-2 in anticancer drug resistance and in other cell behavior, especially cell
proliferation.
C. Down-regulation of mig-2 to further confirm its role
Antisense technology was applied to down-regulate mig-2 mRNA and hence to
reduce the gene product of mig-2. Both antisense oligonucleotide and antisense plasmid
were designed and synthesized. These anti-mig-2 nucleotides were introduced into cell
lines in which mig-2 was expressed, including HCT116 and MCF-7. Cytotoxic assays
and other assays were performed to determine cell sensitivity as well as other cell
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behavior. It was anticipated that down-regulation of mig-2 gene through antisense
technology could help confirm the data obtained from the re-expression experiments.
Briefly, a pilot study was initiated to explore the functional significance of an
uncharacterized gene mig-2 in human cancer cells, focusing on cell susceptibility against
anticancer drugs and cell growth control. Our hypothesis, based on our previous study,
was that mig-2 gene might play a role in conferring cell sensitivity to cytotoxic reagents
in human cancer cells. Additionally, mig-2, as an IE gene in mitogen-mediated signal
transduction, was expected to stimulate or at least participate in cell proliferation. We
began our exploration with cloning and subsequently transfection of mig-2. Three
commonly used anticancer drugs were chosen to examine the relationship between mig-2
expression and cell susceptibility. Furthermore, the stably transfected cell lines were
generated to explore the role of mig-2 in cell behavior, especially in cell growth control.
This study represents the first step to explore mig-2 function in human cancer cell lines.
Obviously, further studies on the underlying mechanisms and pathways involved mig-2
gene are of great interest.
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CHAPTER 2     OBJECTIVES
2.1   Objectives of the study
This study aimed to explore the functional significance of an uncharacterized human
gene mig-2, which shared 60% homology to a novel mouse gene capable of reversing the
acquired drug resistance in murine cells. As an IE gene in the mitogen stimulated signal
transduction, mig-2 was indicated a potential role in cell growth control as well. The
recent study showed that mig-2, as a cell-matrix adhesion protein, functioned in cell
shape modulation in human fibroblast cells WI-38 and mouse C2C12 cells (Tu et al.,
2003). This further raised questions on the potential functions of mig-2.
Based on our preliminary research, we intended to initiate a pilot study to explore the
capability of mig-2 at enhancing cellular susceptibility to cytotoxic agents in human
cancer cell lines. If the gene could be capable of reversing drug resistance of cells to the
cytotoxicity, a new factor involved in drug resistance would then be identified because
there were no data reporting the relationship between mig-2 and cancer cell sensitivity to
chemotherapeutic or toxic agents.
In addition, we would like to explore the possible involvements of mig-2 gene in the
regulation of cancer cell proliferation and apoptosis. The identification process of mig-2
suggested that mig-2 might be involved in the progression of G0S phase transition,
furthermore cell growth control. A database search in GeneServer revealed that mig-2
was included in the gene list in cell cycle control. Because no homology could be found
between mig-2 and any genes currently known to be involved in cell cycle control or
apoptosis, it was worthy to explore if mig-2 was a new member involved in this
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complicated regulatory mechanism. Our study attempted to achieve the following
objectives:
1. cloning mig-2 gene into different plasmids for both cellular localization of mig-2
protein and functional studies of mig-2 gene;
2. examination of the relationship between mig-2 gene expression and cancer cell
susceptibility to cytotoxic reagents;
3. re-expression of mig-2 in human cancer cell lines by transfection to determine the
function of mig-2 in regulation of cell proliferation; and
4. down-regulation of mig-2 in cancer cell lines by antisense technology to confirm
the biological role of mig-2 gene.
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CHAPTER 3     MATERIALS AND METHODS
3.1      Sequence analyses and statistics
Database searches were carried out using BLAST and Swiss-Prot to analyze mig-2
sequence from genome level to protein level. The homologies of mig-2 in different species
were aligned using Clustal W program. The conserved domains within mig-2 protein were
indicated as well.  All statistics were done using Mann-Whitney test and P value <0.05 was
considered significant.
3.2       Cell lines and cell culture
HT29 human colon carcinoma cells were maintained in Dulbecco-Vogt modified Eagle’s
minimum essential medium (DMEM, Sigma, St Louis, MO) supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Trace Scientific Ltd, Melbourne, Australia). MCF-7
human breast cancer cells and Colo205 human colon cancer cells were cultured in RPMI-
1640 (Sigma, St Louis, MO) supplemented with 10% FBS. HCT116 human colon cancer
cells were cultured in McCoy’s 5A (Sigma, St Louis, MO) medium supplemented with 10%
FBS. All cell cultures were obtained from American Type Culture Collection (Rockville,
MD) and incubated at 37°C in humidified incubator containing 5% CO2.
3.3       RNA isolation
Total RNA was isolated from MCF-7 cells using RNeasy Mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol. Briefly cells were cultured to 70%
confluence in a T75 flask, collected by tripsinization and centrifuged at 1000rpm for 5
minutes (min) at room temperature. The cell pellet was then lysed in 650 µl of RLT buffer
containing 6.5 µl of β-mercaptoethanol and homogenized. An equal volume of 70% ethanol
was added and the sample applied to an RNeasy minispin column and centrifuged for 15
seconds (sec) at 13,000 g. The column was washed with 700 µ l of buffer RW1 and
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centrifuged again for 15 sec at 13,000 g. The column was then transferred to a new 2 ml
collection tube and washed with 500 µl of buffer RPE and centrifuge as above. A second
wash step with another 500 µl of buffer RPE was done, followed by centrifugation at 13,000
g for 2 min. The column was transferred to a new 1.5 ml collection tube and RNA was eluted
with 40 µl of DEPC-treated water by centrifugation at 13,000 g for 1 min. All centrifugations
were carried out at room temperature.  The isolated RNA was stored at –80°C.
3.4       One-Step RT-PCR
One-Step RT-PCR was carried out to screen the expression status of mig-2 in different
cancer cell lines. 1µg of total RNA extracted from cell lines was utilized in One-Step
Reverse Transcription Polymerase Chain Reaction (RT-PCR; Qiagen, Hilden, Germany).
2 internal primers were designed for producing a 480 base pairs (bp) fragment of mig-2
DNA. They are 5’-CCTTGTCACCAACTTCTGCT-3’ (MigfrgF) and 5’-
CCTTCCAGAGTAATCTCCAG-3’ (MigfrgR). The reaction was performed as given in
Table 3-1.
TABLE 3-1: One-Step RT-PCR
         Components                                                                 Volume (µl)
  DEPC treated water 29
  5X PCR reaction buffer 10
  dNTP mix (10mM each) 2
  Migfrg F (10mM) 3
  Migfrg R (10mM) 3
  Enzyme Mix 2
  Template RNA (1µg/µl) 1
  Total Volume 50
27
The reaction was overlaid with mineral oil and subjected to PCR using the following
parameters:
                                        1 cycle: 50°C - 30 min
                                        1 cycle: 95°C - 15 min
                                        40 cycles: 94°C - 30 sec
                                                           55°C   -   10 sec
                                                           68°C   -   1 min
                                        1 cycle:      68°C   -   10 min
The PCR products were then analyzed by electrophoresis on 1% agarose gel and visualized
by a gel viewer-EquiChemi II Darkroom (UVP Inc., Upland, CA).
3.5       cDNA synthesis
Five µg of total RNA from MCF-7 cells was utilized in cDNA synthesis using Superscript
II RNase H- Reverse Transcriptase (Invitrogen, Carlsbad, CA) catalyzed transcription
reaction. The primer for cDNA synthesis provided in the kit is 5’-TTTTGTACAAGCTT30-
3’. The first strand synthesis reaction was set up as Table 3-2.
TABLE 3-2: Reverse Transcription
       Components                                                                 Volume (µl)
  Total RNA (1µg/µl)                                                                 5
  dNTP mix (10mM)                                                                  1
  Oligo dT primer                                                                       1
  DEPC water                                                                             5
  React at 65°C for 5 min, mix well and quick spin to collect the products
  5X 1st Strand Buffer                                                                 4
  0.1 M DTT                                                                               2
  RNase inhibitor                                                                        1
  React at 42°C for 2 min
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  Superscript II enzyme                                                              1
  Total Volume                                                                           20
The total reaction was then subject to 42°C for 50 min and 70°C for 15 min. The cDNA was
stored at -20°C.
3.6       PCR amplification of mig-2 full-length cDNA
The cDNA was subsequently subjected to Polymerase Chain Reaction (PCR) using
Advantage 2 PCR Kit (Clontech, Palo Alto, CA). 2 gene-specific primers were designed
according to the sequence information of mig-2 (GenBank accession number: Z_24725) to
generate the full-length of mig-2 cDNA. They are:
Mig bam F: 5’- AGGATCCGGAAGGAGCCATGGCTCTGGA-3’;
Mig xho R: 5’-ACTCGAGCGCAACAGACTAGAACATGGCC-3’.
BamHI and XhoI cutting sites were incorporated into the primers for the purpose of cloning.
The PCR reaction was performed as given in Table 3-3.
TABLE 3-3: PCR amplification of mig-2 cDNA
            Components                                                                   Volume (µl)
  10X Advantage cDNA PCR buffer 5
  dNTP mix (10mM each) 1
  Mig bam F (10mM) 1
  Mig xho R (10mM) 1
  cDNA template 2
  Sterile water 40
  Advantage 2 cDNA polymerase 1
  Total Volume 50
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The reaction was overlaid with mineral oil and subjected to PCR using the following
parameters:
                                        1 cycle: 94°C - 1 min
                                        35 cycles: 94°C - 15 sec
                                                        67°C - 15 sec
                                                        72°C - 4 min
                                        1 cycle: 72°C - 10 min
The PCR products were subsequently analyzed by electrophoresis as described above. The
procedure of generating mig-2 DNA from mRNA was demonstrated in Illustration 3-1.
                                  
                                                Reverse Transcription
                                 5’                                                   AAAAAA 3’    mRNA
                                 3’                                                   TTTTTTT 5’    1 st Strand cDNA
                                                                                                                   
                                                                    PCR                     
            Forward Primer
                                                             ORF of mig-2
                                                                                                                  Reverse Primer
                                          Full-length mig-2 cDNA for cloning
ILLUSTRATION 3-1 The procedure of generating full-length mig-2 cDNA from mRNA                   
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3.7       Cloning mig-2
3.7.1   Purification of PCR product
The PCR product of mig-2 cDNA was isolated from agarose gel and purified using the
phenol-chloroform purifying method. Briefly, the PCR band was cut from the agarose gel
and subjected to a quick spin through glasswool. The extract was increase in volume to 300
µl. The same volume of phenol was then added, mixed and centrifuged at 14K for 5 min at
room temperature. Collect the supernatant into a new tube and add 1 volume of chloroform.
Mix and spin at 14K for 5 min at room temperature. Transfer the supernatant to another tube
and add 2-2.5 volumes ice-cold 100% ethanol and 1/10 volume 3 M sodium acetate. Incubate
the mixture at -80°C for at least 30 min. Centrifuge the mixture at 14K for 15 min at -4°C.
Discard the supernatant and wash the tube using 100 µl of ice-cold 70% ethanol. Invert the
tube and gently rinse for several times. Then centrifuge at 14K for 5 min at room
temperature. Dry the tube completely and dissolve the DNA pellet in approximately 10 µl of
sterile water. Store the DNA at -20°C.
3.7.2    Cloning mig-2 into pcDNA3.1 (+)
The pcDNA3.1 plasmid (Invitrogen, Carlsbad, CA) was chosen for cloning of mig-2
because pcDNA3.1, as a commonly used plasmid, has many features that make it suitable for
transfection in mammalian cells, such as the human cytomegalovirus immediate-early
promoter, the Neomycin resistance gene for selection of stable transfection, the Ampicillin
resistance gene for selection of vector and so on. The structure of pcDNA3.1 (+) and mig-2
insertion were illustrated in Illustration 3-2.
The purified mig-2 cDNA was subjected to the restriction enzyme digestion for the
purpose of ligation into plasmids. BamH I and Xho I were used in this reaction.
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TABLE 3-4: Restriction enzyme digestion with BamH I and Xho I
       Components                                                             Volume (µl)
  10X restriction buffer 1
  BamH I (10U/µl) 1
  Xho I (10U/µl) 1
  DNA/Plasmid 5
  Sterile water 12
  Total Volume 20
The digested fragments were then purified using phenol-chloroform method and subjected to
the ligation reaction as showing in Table 3-5:
TABLE 3-5: Ligation of mig-2 into plasmid
     Components                                                               Volume (µl)
 10X ligase buffer 1
  Mig-2 DNA 3
  Plasmid 1
  Sterile water 4
  Ligase 1
  Total Volume 10
Incubation was carried out at 16°C for 20 h.
3.7.3 Transformation
3.7.3.1 Principle of bacterial transformation in gene cloning
The foreign DNA to be cloned is inserted into plasmids that are derived from bacterial
cells. These plasmids contain an origin of replication and one or more genes that make
the recipient cells resistant to one or more antibiotics. These resistances allow
investigators to select cells that contained recombinant plasmids.  Bacterial cells can take
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up DNA from growing medium. This phenomenon, known as transformation, forms the
basis for cloning plasmids into bacterial cells. In the most commonly employed
techniques, recombinant plasmids are added to a bacterial culture that has been pretreated
with calcium ions. When subjected to a brief heat shock, such bacteria are stimulated to
take up DNA from their surrounding medium. Once it is taken up, the plasmid replicates
autonomously and is passed on to the progeny during cell division. The gene cloning
using bacterial cells transformation was demonstrated in illustration 3-3.
                                                            Mig-2 (~3 kb)
ILLUSTRATON 3-2 Structure of constructed pcDNA 3.1 (+) with mig-2 cDNA
insertion (Source: pcDNA3.1+/- information sheet, invitrogen)
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                                                                                                                                 Plasmid     
                                                E coli chromosome
                                                                                             Purify plasmid DNA
         
          PCR product of mig-2 DNA            
                                                        Treat with BamH I
                                                               and XhoI    
                                          Join fragments
                                        with DNA ligase                    
                                      Plasmid inserted
                                      mig-2 cDNA          
                                                                                     Incubate E. coli cells under certain                  
                                                                                     condition (e.g. heat shock), they will      
                                                                                     take up plasmid DNA.
ILLUSTRATION 3-3 Gene cloning by bacterial transformation
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3.7.3.2 Procedure of transformation by heat shock
The plasmid mixture was transformed into JM 109 competent cells by heat shock. The
brief procedure is: Add 10 µl mixture of ligation reaction to 50 µl of competent cells. Mix by
gently flicking and place the mixture on ice for 30 min. Then heat-shock the mixture in a
42°C for exactly 45 sec. Immediately return the mixture to ice and keep for 2 min. Add 950
µl of LB medium at room temperature. Shake and incubate the mixture at 37 °C for 1.5 h.
Then quick spin the bacteria culture and discard 900 µl of the supernatant. Mix the remaining
100 µl of bacteria culture by flicking gently and plate it onto a LB plate with corresponding
antibiotics. The plate was incubated at 37°C overnight.   
3.7.4 Plasmid miniprep and screening
The following day, about 10 colonies were picked from the plate and grown in 3 ml of LB
medium with certain antibiotics in the shake at 37°C for overnight. The next morning, the
plasmid was extracted from the bacteria culture using Miniprep Kit (Qiagen, Hilden,
Germany). Briefly, quick spin the 3ml of bacteria culture into pellet and discard the
supernatant. Resuspend bacteria pellet into 250 µl of buffer P1 stored at -4°C. Then add 250
µl of buffer P2 and invert gently for 4-6 times to mix. Add 350 µl of buffer N3 and invert the
tube immediately but gently for 4-6 times. Centrifuge the tube at the maximum speed for 10
min. Transfer supernatant to the column provided by pipetting. Then centrifuge the columns
for 30-60 sec and discard the flow-through. Wash the column by adding 0.5 ml of buffer PB
and centrifuge for 30-60 sec and discard the flow-through. Wash again with 0.75 ml of buffer
PE and centrifuge for 30-60 sec. Discard the flow-through and centrifuge again for 1 min.
Transfer the column to a new 1.5-ml microfuge tube and add 50 µl of Buffer EB to the center
of the column. Stand the column for 1 min before spin it for 1 min. Store the plasmid DNA at
-20°C.
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The plasmid DNA was screened by PCR using the internal pair of primers for mig-2. The
reaction was set as Table 3-6.
TABLE 3-6: Plasmid DNA PCR screening
           Components                                                               Volume (µl)
 10X PCR reaction buffer 2.5
  MgCl2 2
  dNTP mix (10mM) 0.5
  Plasmid  DNA 2
  Migfrg F (10mM) 1
  Migfrg R (10mM) 1
  Taq polymerase 0.25
  Sterile water 15.75
  Total Volume 25
The reaction was overlaid with mineral oil and subjected to PCR using the following
parameters:
                                        1 cycle: 94°C - 5 min
                                        35 cycles: 94°C - 30sec
                                                        55°C - 30 sec
                                                        72°C - 1 min
                                        1 cycle: 72°C - 10 min
The PCR products were analyzed using electrophoresis on 1% agarose gel. Positive
plasmid DNA was then subjected to automated sequencing to confirm mig-2 cDNA insertion.
The positive colonies i.e. the bacteria containing the plasmid inserted with full-length mig-2
DNA were cultured in LB medium. Enough plasmid DNA was prepared by miniprep for the
purpose of transfection later on.
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3.8     Automated sequencing
The BigDye sequencing is based on the Sanger-Coulson (or chain termination) method,
which was developed in 1970.  As shown in Illustration 3-6, the DNA is denatured into single
strands and incubated with the sequencing primer, dNTPs mix and a low concentration of
fluorescence-labeled dideoxyribonucleoside triphosphate (ddNTP). Dideoxyribonucleotides
are lack of a hydroxyl group at both their 2’ and 3’ position. Once one of these nucleotides
has been incorporated to the growing chain, it is impossible for the polymerase to add another
nucleotide. Because the ddNTPs are labeled with different colors of fluorescence, it allows
the sequencing machine to determine the last base for the fragments of DNA.
Plasmid DNA was sequenced using an automated sequencer (ABI Prism 377; Amersham).
Sequencing reaction were prepared as follows: 500 ng of double stranded plasmid was added
to a thin wall PCR tube containing 4 µl of BigDye terminator mix (containing terminators
and enzymes; Amersham), 2 µl of 5X sequencing buffer and 3.2 pmol of sequencing primer.
We used T7 primer and Mig xho R or Migfrg F and Migfrg R as sequencing primers
respectively to sequence the full length of mig-2. The final volume for sequencing reaction
was made up to 20 µl with sterile water. The mixture was then subjected to 25 cycles of
thermal sequencing: 95°C for 10 sec, 50°C for 5 sec and 60°C for 4 min. The extension
products were purified by ethanol precipitation. The final pellet was air dried before being
reconstituted in sequencing loading buffer and sequencing using an ABI Prism 377




                                                                           Denature of DNA
3’ CCTGTACTCGA 5’
                                                                           Sequencing primer
                                                                           + DNA polymerase
                                                                           + dNTP
                                                                           + ddNTP
3’ CCTGTACTCGA 5’
                                                        5’ GGA 3’
                     
      ddGTP                     ddATP                ddCTP                           ddTTP          
 GGACATG               GGACA                  GGAC                      GGACAT
 GGACATGAG         GGACATGA          GGACATGAGC      GGGACATGATGAGCT    
                                                                                   CATGAGCT
                                                                            
                                                                                   CATGAGC
                                                                            
                                                                                   CATGAG
                                                                             
                                                                                   CATGA
                                                                             
                                                                                   CATG                                                                             
                                                                                   CAT                                                                             
                                                                                   CA                                                                             
                                                                                   C            
ILLUSTRATION 3-4 Principle of BigDye sequencing
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3.9      Transfection
3.9.1   Principle of cationic lipid mediated transfection
Cationic lipid reagents form small (average size 100 to 400 nm) unilamellar liposomes
when formulated in water under optimal conditions. The surface of these liposomes is
positively charged and is attracted electrostatically to the phosphate backbone of DNA, as
well as to the negatively charged surface of the cell membrane. The principle of delivery
using cationic lipid reagents is: the negatively charged DNA binds spontaneously to the
positively charged liposomes, forming DNA-cationic lipid reagent complexes (Illustration 3-
5). It is believed that two to four liposomes associate with a single plasmid of about 5 kb
(Felgner et al., 1987). The captured DNA is delivered to cultured cells. Evidence exists that
the mechanism of DNA delivery is through endosomes and lysosomes (Coonrod et al., 1997).
ILLUSTRATION 3-5 Principle of cationic lipid medicated transfection
(Source: Guide to Eukaryotic transfection with cationic lipid reagent, Invitrogen)
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3.9.2   Transient transfection
3.9.2.1 Optimization for transfection efficiency
Transfection efficiency is critical for transient transfection of a gene into cells. We use
pEGFP-N2 to optimize the transfection in HT29 cells. Basically two parameters were
optimized: the amount of transfection reagent and the duration of incubation. Briefly, HT29
cells were seeded in 6-well plate at a density of 104 cells/cm2 the day before transfection. 1
µg of plasmid DNA was transfected into cells using Lipofectamine PlusTM Reagent
(Invitrogen, Carlsbad, CA). The detailed procedure for transfection was described later. In
the purpose of optimization, we set up two groups, one using 3 µl of PLUS reagent and 2.5 µl
of LIPOFECTAMINE reagent; the other 6 µ l of PLUS reagent and 4 µ l of
LIPOFECTAMINE reagent. Both groups were in duplicate, one was incubated for 3 h
(recommended in protocol), the other overnight. The transfection efficiency was examined
under a fluorescence microscope. Transfected cells were in green color. The average
transfection efficiency was determined by the ratio between cells with green fluorescence and
the total cell number at four randomly selected views.    
3.9.2.2 Procedure of optimized transfection
After optimizing the amount of transfection reagent and duration of incubation with DNA-
transfection reagent complex, the transfection was performed according to the optimal
procedure. HT29 cells were seeded (104 cells/cm2) into 6-well plates 24 h prior to
transfection. The 50-70% confluent cells were then transfected by constructed as well as
plasmid DNA alone using Lipofectamine PlusTM Reagent. The brief procedure is: Dissolve 1
µg of plasmid DNA into 100 µl of serum-free culture medium and mix. Pre-complex the
DNA with 3 µl of PLUS Reagent and incubate for 15 min at room temperature. Dilute 2.5 µl
of LIPOFECTAMINE Reagent into 100 µl of serum-free medium in a second tube and mix.
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Combine pre-complexed DNA with diluted LIPOFECTAMINE Reagent, mix and incubate
for 15 min at room temperature. While the complexes are forming, replace the medium on
cells with 800 µl of serum-free medium. Add the DNA-PLUS-LIPOFECTAMINE Reagent
complexes to each well and incubate at 37°C at 5% CO2 for 3 h. After incubation, replace the
medium with full culture medium. The whole procedure of transfection was illustrated in
Illustration 3-6. For transient transfection, cells were subjected to certain treatments 24 h
after transfection.
ILLUSTRATION 3-6 Procedure of cationic lipid mediated transfection
        (Source: General protocol for LIPOFECTAMINE PLUS TM Reagent, Invitrogen)
41
3.9.3 Stable transfection
3.9.3.1 Principle of stable transfection
Transfecting the gene of interest along with a selectable marker for drug resistance is one
of the most common methods to establish a stably transfected cell line. The aminoglycoside
phosphotransferase gene (APH or neor) confers resistance to Geneticin selective antibiotic
(G418; Sigma, St Louis, MO) by directing the synthesis of the APH enzyme that renders the
drug inactive through phosphorylation. The antibiotic resistance marker can be carried on the
same plasmid as the gene of interest. Wait 48 h to 72 h following transfection before
beginning of selection. This allows the cells to express adequate amounts of the resistance
enzyme to protect them when selection begins. 48 h to 72 h after transfection, we remove the
medium and replace it with medium containing the concentration of Geneticin adequate to
kill all non-transfected cells. The principle of establishing the stable cell line is demonstrated
in illustration 3-7.
3.9.3.2 Determination of Geneticin (G418) concentration
Since many factors affect the optimal concentration of Geneticin antibiotic required for
selection, including cell type culture medium and serum concentration, it is necessary to
perform a dose response curve to determine the optimal concentration for each cell type.
We tested a range of concentrations to determine the optimal concentration that we used
in our selection. The brief procedure is: seed cells at approximately 25% confluent in a
set of 8 plates the day before Geneticin treatment. The next day, substitute culture
medium with medium containing varying concentrations of Geneticin  (0, 50, 100, 200,
400, 500, 600, 800 µl/ml Geneticin). Replenish the selective medium every 2-3 days.
Observe the percentage of surviving cells and determine the concentration at which
growth inhibition occurred within 2-3 weeks after addition of Geneticin. Based on our
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observation, the appropriate concentration of Geneticin was 500 µg/ml for HT29 and 800
µg/ml for HCT116. The selection procedure is illustrated briefly in illustration 3-8.
                                                                                                                                     Geneticin
                                                                                                                                    resistance
                                                                          transfection                                        gene   
                                                                                                                pcDNA    
                                                                                                        
                                                                                                                                        mig-2
                                                                           after 24-48 h, change medium with
                                                                           500 ug/ml Geneticin
                                                                     
                                                                           Culture for 2 weeks
                                                                                                        Incorporated genes
                                                                                                                   Cell Genome
                                                    
                                                                                                                                 
               Expand survived cells
               (stable cell line)
ILLUSTRATION 3-7 Principle of establishing stable cell line
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       Seed cells at same density and treat with Geneticin in a range of concentration (µg/ml)                        
                                   0                          50                   100                   200
                                    400                   500                   600                   800
                              Culture for 14 days
                       Observe cell survival and determine the optimal concentration
                                      0                       50                   100                  200
                                     400                  500                  600                   800
          
ILLUSTRATION 3-8   The determination of optimal concentration for Geneticin
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3.9.3.3 Selection of stably transfected cell line
For generating stably transfected HT29 cell line, 500 µg/ml Geneticin was added into
culture medium 24 h after the transfection. The cells were cultured for 14 days with medium
changed every 2 days. Colonies of cells were harvest and subsequently cultured in a 75cm2
flask in medium with 500 µg/ml Geneticin. The expression of mig-2 gene was detected using
One-Step RT-PCR. The stably transfected cell lines were then maintained in the medium
containing 500 µg/ml Geneticin.
3.10   Proliferation and cytotoxicity assays
3.10.1    MTT assay
3.10.1.1 Principle of MTT assay
MTT assay was first used to carry out cytotoxicity assay in the early eighties (Raff, 1992).
The National Cancer Institute (NCI) evaluated MTT-dye reduction as a possible endpoint in a
rapid screening assay (Williams and Smith, 1993) and this stimulated interest in the wider
scientific community. MTT (3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyl-tetrazolium bromide;
Sigma) is a water-soluble chemical. Active mitochondrial dehydrogenases of living cells
convert the yellowish MTT to an insoluble purple formazan. This conversion does not take
place in dead cells. This water-insoluble formazan can be solved using isopropanol, and the
dissolved material can be measured spectrophotometrically. Thus the amount of viable cells
can be measured accordingly.
3.10.1.2   Optimization of the parameters of MTT assay
To measure the cell sensitivity by MTT successfully, it is important to optimize two
parameters: initial cell density and the incubation duration. The aim for cell density
optimization is to remain the cells in exponential growth throughout the assay. If cells in the
control wells i.e. those not exposed to drug become confluent they will stop dividing while
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the drug treated cells will continue growth. As a result, drug sensitivity will be under-
estimated since the control absorbance will be lower than it should be. Similarly, the duration
of MTT incubation needs to be determined because a short duration is not enough for the
formazan forming, while a long duration leads to the formazan formation reach a platform
thus reduce the sensitivity of MTT.   
Briefly, we seeded cells in a 96-well plate. The initial cell density ranged from 5 x 102 to
1.6 x 104 cells/well. The cells were fed daily for 4 days. Incubate the plate with MTT and
select the density that gives a MTT reading around 1. This density was the optimal density
for MTT assay. For the duration of incubation, we prepared cells at the same range of density
in four 96-well plates and incubated with MTT for 1 h, 2 h, 3 h and 4 h respectively. The
duration at which the reading appeared distinctive difference was chosen as the optimal
incubation duration.
3.10.1.3   Procedure of optimized MTT assay
The medium on the drug-treated cells was replaced with 50 µl of MTT mixed with the
same volume of culture medium. The cells were then incubated at 37°C with 5% CO2 for 4 h.
The purple formazan was dissolved into 200 µl of lysis buffer (isopropanol with 4% HCl).
The plate was covered with aluminum foil and shake on an orbital shaker at 50 rpm at room
temperature for 1 h. Transfer the dissolved formazan into a 96-well plate and measured the
optical density at 570 nm.
3.10.2  Drug treatment
Three commonly used anticancer drug: etoposide, staurosporine and 5-FU were chosen to
perform drug treatment.  
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3.10.2.1   Optimization for drug concentration and duration
Due to the various cytotoxic capabilities in different drugs as well as different sensitivity
depending on cell types, an optimal range of drug concentration needs to be determined. The
cells were seeded at the optimal density in a 96-well plate in triplicates the day before drug
treatment. A wide range of concentration of drugs (1-50 µM for etoposide and 5-FU; 6.25-
400 nM for staurosporine) was used to treat the cells. MTT was then performed to determine
the killing effects. The optimal range we chose was from the concentration at which the drug
started to kill cells to the concentration at which around 70% cells were killed.
3.10.2.2   Optimized anticancer drug treatment
Mig-2 stably transfected HT29 cells were cultured in 24-well plate at a density of 2 x 104
cells/well 24 h prior to the exposure of drugs. The cells were then cultured in the presence the
optimal range of concentrations of etoposide (2.5-40 µM), staurosporine (12.5-200 nM) and
5-FU (2.5-40 µM) respectively. After 24 h incubation with drug exposure, the medium
containing drugs were replaced by fresh culture medium. Cells were continued to culture for
additional 48 h before subjected to cytotoxicity assay.
3.11 Cell growth
3.11.1  Cell growth curve
The growth curves of stably transfected HT29 cells with mig-2 construct or empty vector
were determined by the following procedure: Seed the two cell lines in 6-well plate
respectively at the same cell densities (5 x 103/well). After 24 h the number of viable cells
was counted using tryphan blue staining. The culture medium was changed every 2 days and
the number of viable cells was counted everyday. The growth curves were drawn according
to the cell numbers.
47
3.11.2 Colony formation
HT29 cells were seeded in a 100 cm2 cell culture plate 24 h prior to transfection. Mig-2
construct or empty vector was transfected into cells. 24 h after transfection, the culture
medium was replaced by the medium containing 500 µg/ml Geneticin. The cells in plated
were cultured for 21 days with medium changed every two days. Colonies of cells were then
counted and photographed.
3.12   Apoptosis detection
3.12.1 Flow cytometry
HT29 cells (2 x 106 /well) growing in 6-well plates were transfected with 1µg of mig-2
construct or empty vector respectively. 48 h after the transfection the cells were harvested
using cell scrapers and resuspended in ice-cold 70% ethanol. The cells were then stored at -
20°C until analysis (no more than two weeks). Before analysis, the stored cells were
centrifuged at the maximum speed for 5 min at 4°C. the cell pellets were then dissolved in 1X
PBS with 200ug/ml DNase-free RNase A and incubated at 37°C for 30 min. The cellular
DNA was then stained with 1mg/ml propidium iodide (PI; Sigma, St Louis, MO). Flow
cytometry was performed on a Coulter EPICS® Elite Flow Cytometer (Coulter Corporation,
Miami, FL). The cell cycle phase distribution was analyzed using WinMDI 2.8 software
program.
3.12.2    TUNEL assay
3.12.2.1   Principle of TUNEL assay
Apoptosis in many cell types is characteristic by the generation of DNA fragments though
the action of endogenous endonucleases (Schwartzman and Cidlowski, 1993; Oberhammer et
al., 1993). The DNA of apoptotic cells is cleaved into multimers of 180-200bp fragments,
corresponding to the oligonucleosomal size. Therefore, the DNA of apoptotic cells typically
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migrates as a ladder of 180-200 bp multimers on an agarose gel (Bortner et al., 1995). The
TdT-mediated dUTP Nick-End Labeling (TUNEL) assay measures the fragmented DNA of
apoptotic cells by catalytically incorporating fluorescin-12-dUTP (a) at 3’-OH DNA ends
using enzyme Terminal Deoxynucleotidyl Transferase (TdT). TdT forms a polymeric tail on
fragmented DNA (Illustration 3-9). The flluorescin-12-dUNT-labeled DNA can be visualized
directly by fluorescence microscopy.
                                                                                       3’
                                                                                                                     Fragmented DNA
      
                                                                          5’
                                                      +  TdT
                                                      +  fluorescin-12-dUTP (a)
                                                                        
                                                                         3’
                                            
                                                                5’
ILLUSTRATION 3-9 Principle of TUNEL labeling with fluorescence
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3.12.2.2   Procedure of TUNEL assay
HT29 cells were grown on coverslips in a 6-well plate for 24 h and then transfected with 1
µg of either mig-2 inserted pcDNA3.1 (+) plasmid or plasmid DNA alone as control. 48 h
after transfection, coverslips were picked up and subjected to TUNEL assay for apoptosis
detection using the DeadEndTM Fluorometric TUNEL System (a) Kit (Promega, Madison,
WI). Briefly, fix cells on coverslips by immersing in freshly prepared 4% methonal-free
formaldehyde solution in PBS (pH 7.4) for 25 min at 4°C. Wash the coverslips twice by
immersing in fresh PBS for 5 min at room temperature. Permeabilize cells by immersing in
0.2% Triton® X-100 solution in PBS for 5 min. Rinse the coverslips twice using fresh PBS
for 5 min at room temperature. Cover the cells with 100 µl of Equilibration Buffer (provided
in the kit) and equilibrate cells at room temperature for 5-10 min. Thaw the Nucleotide Mix
on ice and prepare sufficient TdT incubation buffer for all the experimental and optional
positive control reactions as Table 3-7.
TABLE 3-7: Preparation of TdT incubation buffer
  Buffer Component                                           Volume (µl) per reaction
  Equilibration Buffer                                                     45
  Nucleotide Mix                                                             5
  TdT Enzyme                                                                 1
  Total Volume                                                                51
Add 50 µl of TdT incubation buffer on the cells and cover cells with plastic coverslips to
ensure even distribution of the reagent. Incubate cells at 37 °C for 60 min inside the
humidified chamber to allow the tailing reaction to occur. Cover the cells with aluminum foil
to protect from direct light. Immerse the coverslips in the 1:10 diluted 20X SSC with
deionized water for 15 min at room temperature to terminate the reaction. Wash 2-3 times
50
with fresh PBS for 5 min at room temperature. Stain the samples by immersing the coverslips
in 5 ml of propidium iodide solution freshly prepared to 1 µg/ml in PBS for 15 min at room
temperature in the dark. Wash cells 2-3 times in deionized water for 5 min at room
temperature. Drain off excess water from the coverslips. The coverslips were mounted on
glass slides using FluorSave TM Reagent (Calriochem). Analyze samples under fluorescence
microscope using a standard fluorescin filter set to view green fluorescence of fluorescin at
520 nm. The slides can be stored at 4 °C in the dark.
3.13  Serum starvation and stimulation
Since mig-2 gene was identified in the process of serum stimulation in the quiescent
human fibroblasts cells, we performed an experiment of serum starvation and stimulation to
confirm the relationship between expression of mig-2 gene and serum treatment in human
cancer cells. The brief experimental procedure was: we chose HCT116 and HL60 in which
mig-2 gene was highly expressed to do serum starvation. The two cell lines were cultured in
75cm2 flask in duplicates with serum-free culture medium for 72 h. Total RNA was extracted
from the cells in one flask. 10% FBS was added to the cells in the other flask and the cells
were continued to culture for another 4 h before RNA extraction. The total RNA was
subjected to One-Step RT-PCR to detect the expression status of mig-2 gene.
3.14   Cellular localization of mig-2
The GFP fusion protein was utilized to determine the cellular localization of mig-2
protein. The ORF of mig-2 was generated by PCR. The 2 primers designed for this purpose
were: GFP xhoF: 5’-CGTGTACGGTGGGAGGTCTCTAT-3’;
GFP bamR: 5’-CGCGGATCCAACCACTGGTAAGTTTGTAG-3’. XhoI and BamHI
cutting sites were inserted into the primers for the purpose of cloning. The PCR reaction was
set as given in Table 3-8.
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TABLE 3-8: PCR amplification of mig-2 ORF
             Components                                                                     Volume (µl)
  10X Advantage cDNA PCR buffer 5
  dNTP mix (10 mM each) 2
  GFP xhoF (10 mM) 2
  GFP bamR (10 mM) 2
  DNA template 2
  Sterile water 36
  Advantage 2 cDNA polymerase 1
  Total Volume 50
The reaction was overlaid with mineral oil and subjected to PCR using the following
parameters:
                                        1 cycle: 94°C - 5 min
                                        35 cycles: 94°C - 15 sec
                                                        65°C - 15 sec
                                                        72°C - 4 min
                                        1 cycle: 72°C - 10 min
The PCR products were subsequently analyzed by electrophoresis and purified using
pheno-chloroform method. The mig-2 ORF DNA was then digested with Xho I and BamH I
(Promega) and ligated in frame to the pEGFP-N2 (Clontech, Palo Alto, CA). The
construction of mig-2 ORF and pEGFP-N2 was demonstrated in illustration 3-10. Automated  
sequencing was performed to confirm the correct insertion. The plasmid encoding mig-2-
GFP fusion protein was transfected into MCF-7 and HT 29 cells respectively growing on
coverslips using Lipofectamine PlusTM Reagent. Coverslips were fixed in 3.7% parafamalde
at 37°C for 10 min and mounted on glass slides using FluorSave TM Reagent (Calriochem).
The cells were subsequently examined under a fluorescence microscope using a standard
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fluorescin filter set to view green fluorescence of fluorescin at 520 nm. The slides can be
stored at 4 °C in dark. Cells transfected with empty pEGFP-N2 served as control.
                                                                             Mig2 ORF~2kb
ILLUSTRATION 3-10  The construction of mig-2 ORF into pEGFP-N2
(Source: Clontech pEGRP-N2 information sheet)
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3.15   Antisense technology
Antisense technology was utilized to down regulate the expression of mig-2 gene.
Two types of mig-2 antisense were used in our study. One was the synthesized antisense
oligonucleotide, and the other was the plasmid inserted with mig-2 sequence in antisense
orientation.
3.15.1 Principle of antisense technology
Antisense technology encompasses all the technologies based on oligonucleotides and
their analogues for exogenous modulations of the flow of genetic information (Milligan et
al., 1993). As shown in illustration 3-11, this interference can be accomplished at any point
of the information flow: at the storage level (antigen), by the use of a triple-helix forming
oligonucleotide and at information processing level (anti-messenger) by the use of an
oligonucleotide directed against mRNA. Obviously, many mechanisms may be involved in a
successful suppression of a gene using antisense technology.  The critical factors for a
successful antisense include the local target RNA structure, chemical properties and
sequences of the oligos, the characteristics of the biological system and gene product, etc.
(Far et al., 2001). Thus it has been found that only limited portion of gene could be
successfully suppressed by antisense technology (Peyman et al., 1995; Monia et al., 1996).
As an uncharacterized gene, mig-2 has not been reported suppressed by antisense technology.
3.15.2 Antisense oligonucleotide    
Application of antisense oligonucleotides allows us to down-regulate mRNA of a gene
and hence to reduce protein levels in mammalian cells (Melendez et al. 1998). Anti-mig
oligonucleotides were designed corresponding to the first 19 coding nucleotides for mig-2
and one base before coding sequence. The location for antisense oligos was determined, to
some extent, empirically based on the facts that the antisense oligos near the translational
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start site seemed to be preferred and to be rewarding target region (Probst, 2000). However,
we analyzed the complete mRNA sequence of mig-2 using two web servers: mfold and
RNAfold. As shown in Figure 3-1, the analyzing by these servers indicated that there are no
complicated helix near the start site and most of the bases within this region are kept single
stranded.    
The oligonucleotides were purchased from QIAGEN Operon oligonucleotides. 20-mers
were synthesized, capped at either end by the phosphorothiorate linkages (first two and last




ILLUSTRATION 3-11 Principle of antisense technology
(Source: Probst, 2000, Methods)
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                                                                                                       Start codon    
GCGCUGUGUCUCGGGGCCGGCCGGCAGGAAGGAGCCAUGGCUCUGGACGG
  )  ) )  ) )  ) ) .  )  )  ) ) )  )  ) .  )  ) . (  ( (  .  .  .  . (  .  .  . (  ( (  ( (  .  .  . .   ) ) )  )  ) . .  .  )  .  .
GAUAAGGAUGCCAGAUGGCUGCUACGCGG  165----
 .  .  .  .  . )  ) )  )  ) )  ) ) .  )  )  )  ) ) ) . ) ) ) . ( . . . (  (
B
-----87 G C G  C U G U G U C U C G G G G C C G G C C G G C  A G G  A A G G A G ss        
18  5  1    0  0   8 18 18  0   0   0  0  0   9 13  1 17  0 13 12 12 1 12 17 17 30 26 26 26 26  0   0  0   0
  
C C A U G G C U C U G G A C G G G A U A A G G A U G C C A G A U G G C U G
 0 25 26 26 26 0  4   1   1  0 25 29 29 22 1  1  21  0   1  22 30 22 21 8  0 21  0  7  29 29 12 2   0  0   0  0   1
C U A C G C G G 165----
18 26 26 1  1   0  0   0
C
                                     _ 110  GCAGGAA   120   C
                                                                 GGAGC    A
                 CGGCCG                              UCUCG      U
                 GUCGGU                                               G
                                   \ _ _ _ _ _ _ _ _ _
                                              130                
                                                              140
                                        GGAC       G      A
                                                    GG    AU   A
                                                    CC    UA   G
                                   AGA_ _ _       G      G
                              150
FIGURE 3-1 mRNA secondary structure prediction using web servers A: Results page
from RNAfold (part): based pairs were denoted by brackets, dots denoted unpaired bases.
The chosen location for antisense oligonucleotides was underlined. B: ss-count of mfold
(part): the number corresponding to each base is the times the base is single stranded in a
group of predicted foldings. C: the secondary structure of mRNA predicted by mfold.   
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HCT116 cells were incubated for 24 h and then transfected with 1 µM oligonucleotides using
LIPOFECTAMINE transfection kit following the same procedure mentioned above for a
total of 24 h. The cells were then subjected to One-Step RT-PCR and drug treatments.
3.15.3      Antisense plasmid
3.15.3.1   Cloning mig-2 antisense into pcDNA3.1 (+)
In order to construct a mig-2 antisense plasmid, two restriction enzymes EcoR I and Not I
were chosen to digest mig-2 sequence. The fragment was subsequently cloned into
pcDNA3.1 (+) in the antisense orientation. The orientation and the sequence of the insertion
were confirmed by automated sequencing.
3.15.3.2   Transfection of antisense plasmid and selection
One µg mig-2 antisense construct or the empty vector DNA was transfected into HCT116
colon cancer cells using the LIPOFECTAMINE transfection kit following the same
optimized procedure as above. The cells were subsequently subjected to One-Step RT-PCR
to examine the down-regulatory effect of the antisense plasmids. Considering the relatively
low transfection efficiency for transient transfection, the selection for stably transfected cells
with mig-2 antisense plasmid was also performed. The cells were selected by culturing in the
medium with presence of 800 µg/ml of Geneticin (the optimized minimum concentration for
HCT116) for 3 weeks. The colonies of cells were then harvested and maintained as stably
transfected cell lines. One-Step RT-PCR was performed to detect mig-2 gene expression in
the cells.
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CHAPTER 4   RESULTS
4.1      Sequence analyses and bioinformatics
4.1.1   Mig-2 in human genome
GenBank search showed that mig-2 was mapped to human chromosome 14q22.1-
q22.3 (Illustration 4-1). The genomic DNA is 93,874 bp with 15 exons (GenBank
accession number: NT_026437), as shown in Illustration 4-2.
4.1.2   Mig-2 cDNA sequence
The full-length cDNA of mig-2 is 3270 bp (GenBank accession number: Z24725), as
shown in Illustration 4-3. The two pairs of primers for either full length DNA cloning or
for screening mig-2 expression were underlined in the sequence. The start codon and stop
codon for mig-2 ORF were also highlighted.
4.1.3    Mig-2 protein
The ORF of mig-2 encodes a 680 amino acid protein (GenBank accession number:
NP006823), as illustrated in Illustration 4-3. The primary structure of mig-2 protein was
analyzed to predict functions of the molecule. BLink analysis (NCBI) revealed that mig-2
has a homology with human talin at C-terminal and with filopodin, Dictyostelium talin
homolog at both C-terminal and N-terminal (Illustration 4-4). Conserved Domain
BLAST search showed that mig-2 protein has a PH domain flanked by 2 FERM domains
(Illustration 4-4).
74 BLAST hits of mig-2 protein in 11 unique species were found. All the hits in
human were demonstrated in Table 4-1 and the top hits in each species were listed in
Table 4-2. Among them the UNC-112 and URP-1 were intensively investigated recently.
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Mig-2 protein sequence was aligned with 4 homologies in other species including
Caenorhabditis elegans,  Mus musculus, Drosophila melanogaster and Ciona intestinalis.
Interestingly, we found the highly conserved sequence at C-terminal of these homologues
(Illustration 4-5).
ILLUSTRATION 4-1 Gene map of mig-2 mig-2 sequence hits chromosome 14q
59
Chromosome 14
                                                  14q22
 1514131211 10 98  7  65         4                             3                                     21
0         10         20         30         40         50          60         70         80         90       100kb
ILLUSTRATION 4-2 Detailed map of mig-2 gene in human genome 15 exons of
mig-2 were shown as bars.      
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   1 CAAAAAGTGTGTGGAAAGGTGGATTGAGGGAGCGGGACCCCCGCGGGACCCGAGGGGGCG   
  61 GCAGGCGGGGAACGGGGAGTCAGCCCGCGCTGTGTCTCGGGGCCGGCCGGCAGGAAGGAGa   
 121 CCATGGCTCTGGACGGGATAAGGATGCCAGATGGCTGCTACGCGGACGGGACGTGGGAAC
   1    M  A  L  D  G  I  R  M  P  D  G  C  Y  A  D  G  T  W  E
 181 TGAGTGTCCATGTGACGGACCTGAACCGCGATATCACCCTGAGAGTGACCGGCGAGGTGC
  20 L  S  V  H  V  T  D  L  N  R  D  I  T  L  R  V  T  G  E  V     
 241 ACATTGGAGGCGTGATGCTTAAGCTGGTGGAGAAACTCGATGTAAAAAAAGATTGGTCTG
  40 H  I  G  G  V  M  L  K  L  V  E  K  L  D  V  K  K  D  W  S       
 301 ACCATGCTCTCTGGTGGGAAAAGAAGAGAACTTGGCTTCTGAAGACACATTGGACCTTAG
  60 D  H  A  L  W  W  E  K  K  R  T  W  L  L  K  T  H  W  T  L
 361 ATAAGTATGGTATTCAGGCAGATGCTAAGCTTCAGTTCACCCCTCAGCACAAACTGCTCC
  80 D  K  Y  G  I  Q  A  D  A  K  L  Q  F  T  P  Q  H  K  L  L         
 421 GCCTGCAGCTTCCCAACATGAAGTATGTGAAGGTGAAAGTGAATTTCTCTGATAGAGTCT
 100 R  L  Q  L  P  N  M  K  Y  V  K  V  K  V  N  F  S  D  R  V
 481 TCAAAGCTGTTTCTGACATCTGTAAGACTTTTAATATCAGACACCCCGAAGAACTTTCTC
 120 F  K  A  V  S  D  I  C  K  T  F  N  I  R  H  P  E  E  L  S
 541 TCTTAAAGAAACCCAGAGATCCAACAAAGAAAAAAAAGAAGAAGCTAGATGACCAGTCTG
 140 L  L  K  K  P  R  D  P  T  K  K  K  K  K  K  L  D  D  Q  S
 601 AAGATGAGGCACTTGAATTAGAGGGGCCTCTTATCACTCCTGGATCAGGAAGTATATATT
 160 E  D  E  A  L  E  L  E  G  P  L  I  T  P  G  S  G  S  I  Y  
 661 CAAGCCCAGGACTGTATAGTAAAACAATGACCCCCACTTATGATGCTCATGATGGAAGCC
 180 S  S  P  G  L  Y  S  K  T  M  T  P  T  Y  D  A  H  D  G  S
 721 bCCTTGTCACCAACTTCTGCTTGGTTTGGTGACAGTGCTTTGTCAGAAGGCAATCCTGGTA
 200 P  L  S  P  T  S  A  W  F  G  D  S  A  L  S  E  G  N  P  G
 781 TACTTGCTGTCAGTCAACCAATCACGTCACCAGAAATCTTGGCAAAAATGTTCAAGCCTC
 220 I  L  A  V  S  Q  P  I  T  S  P  E  I  L  A  K  M  F  K  P   
 841 AAGCTCTTCTTGATAAAGCAAAAATCAACCAAGGATGGCTTGATTCCTCAAGATCTCTCA
 240 Q  A  L  L  D  K  A  K  I  N  Q  G  W  L  D  S  S  R  S  L
 901 TGGAACAAGATGTGAAGGAAAATGAGGCCTTGCTGCTCCGATTCAAGTATTACAGCTTTT
 260 M  E  Q  D  V  K  E  N  E  A  L  L  L  R  F  K  Y  Y  S  F   
 961 TTGATTTGAATCCAAAGTATGATGCAATCAGAATCAATCAGCTTTATGAGCAGGCCAAAT
 280 F  D  L  N  P  K  Y  D  A  I  R  I  N  Q  L  Y  E  Q  A  K
1021 GGGCCATTCTCCTGGAAGAGATTGAATGCACAGAAGAAGAAATGATGATGTTTGCAGCCC
 300 W  A  I  L  L  E  E  I  E  C  T  E  E  E  M  M  M  F  A  A
1081 TGCAGTATCATATCAATAAGCTGTCAATCATGACATCAGAGAATCATTTGAACAACAGTG
 320 L  Q  Y  H  I  N  K  L  S  I  M  T  S  E  N  H  L  N  N  S
1141 ACAAAGAAGTTGATGAAGTTGATGCTGCCCTTTCAGACCTGGAGATTACTCTGGAAGGGGc
 340 D  K  E  V  D  E  V  D  A  A  L  S  D  L  E  I  T  L  E  G   
1201 GTAAAACGTCAACAATTTTGGGTGACATTACTTCCATTCCTGAACTTGCTGACTACATTA
 360 G  K  T  S  T  I  L  G  D  I  T  S  I  P  E  L  A  D  Y  I     
1261 AAGTTTTCAAGCCAAAAAAGCTGACTCTGAAAGGTTACAAACAATATTGGTGCACCTTCA
 380 K  V  F  K  P  K  K  L  T  L  K  G  Y  K  Q  Y  W  C  T  F     
1321 AAGACACATCCATTTCTTGTTATAAGAGCAAAGAAGAATCCAGTGGCACACCAGCTCATC
 400 K  D  T  S  I  S  C  Y  K  S  K  E  E  S  S  G  T  P  A  H
1381 AGATGAACCTCAGGGGATGTGAAGTTACCCCAGATGTAAACATTTCAGGCCAAAAATTTA
 420 Q  M  N  L  R  G  C  E  V  T  P  D  V  N  I  S  G  Q  K  F
1441 ACATTAAACTCCTGATTCCAGTTGCAGAAGGCATGAATGAAATCTGGCTTCGTTGTGACA
 440 N  I  K  L  L  I  P  V  A  E  G  M  N  E  I  W  L  R  C  D    
1501 ATGAAAAACAGTATGCACACTGGATGGCAGCCTGCAGATTAGCCTCCAAAGGCAAGACCA
 460 N  E  K  Q  Y  A  H  W  M  A  A  C  R  L  A  S  K  G  K  T
1561 TGGCGGACAGTTCTTACAACTTAGAAGTTCAGAATATTCTTTCCTTTCTGAAGATGCAGC
 480 M  A  D  S  S  Y  N  L  E  V  Q  N  I  L  S  F  L  K  M  Q     
1621 ATTTAAACCCAGATCCTCAGTTAATACCAGAGCAGATCACGACTGATATAACTCCTGAAT
 500 H  L  N  P  D  P  Q  L  I  P  E  Q  I  T  T  D  I  T  P  E    
1681 GTTTGGTGTCTCCCCGCTATCTAAAAAAGTATAAGAACAAGCAGATAACAGCGAGAATCT
61
 520 C  L  V  S  P  R  Y  L  K  K  Y  K  N  K  Q  I  T  A  R  I    
1741 TGGAGGCCCATCAGAATGTAGCTCAGATGAGTCTAATTGAAGCCAAGATGAGATTTATTC
 540 L  E  A  H  Q  N  V  A  Q  M  S  L  I  E  A  K  M  R  F  I     
1801 AAGCTTGGCAGTCACTACCTGAATTTGGCATCACTCACTTCATTGCAAGGTTCCAAGGGG
 560 Q  A  W  Q  S  L  P  E  F  G  I  T  H  F  I  A  R  F  Q  G    
1861 GCAAAAAAGAAGAACTTATTGGAATTGCATACAACAGACTGATTCGGATGGATGCCAGCA
 580 G  K  K  E  E  L  I  G  I  A  Y  N  R  L  I  R  M  D  A  S    
1921 CTGGAGATGCAATTAAAACATGGCGTTTCAGCAACATGAAACAGTGGAATGTCAACTGGG
 600 T  G  D  A  I  K  T  W  R  F  S  N  M  K  Q  W  N  V  N  W   
1981 AAATCAAAATGGTCACCGTAGAGTTTGCAGATGAAGTACGATTGTCCTTCATTTGTACTG
 620 E  I  K  M  V  T  V  E  F  A  D  E  V  R  L  S  F  I  C  T    
2041 AAGTAGATTGCAAAGTGGTTCATGAATTCATTGGTGGCTACATATTTCTCTCAACACGTG
 640 E  V  D  C  K  V  V  H  E  F  I  G  G  Y  I  F  L  S  T  R  
2101 CAAAAGACCAAAACGAGAGTTTAGATGAAGAGATGTTCTACAAACTTACCAGTGGTTGGG
 660 A  K  D  Q  N  E  S  L  D  E  E  M  F  Y  K  L  T  S  G  W   
2161 TGTGAATAGAAATACTGTTTAATGAAACTCCACGGCCATAACAATATTTAACTTTAAAAG



















ILLUSTRATION 4-3 The full-length cDNA sequence of mig-2 and its coding amino
acid sequence The start codon and stop codon were in bold and underlined. The location
of primers for cloning and for screening were underlined and indicated as follow: a: Mig
bam F; b: Migfrg F; c: Migfrg R; d: Mig xho R. The sequences of conserved domains in
mig-2 protein were demonstrated in bold italic.
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                                                                                                                    680 amino acids
NH2       Filopodin                     FERM     PH       FERM       Talin & Filopodin     COOH
ILLUSTRATION 4-4  Schematic representation of primary structure of mig-2
protein   FERM, PH, and talin homology domains are demonstrated as boxes.
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TABLE 4-1 The BLAST hits of mig-2 protein in human
SCORE   P    ACCESSION          GI                        PROTEIN DESCRIPTION
3582 27 AAH17327 16878257 Pleckstrin homology domain containing,    
                                                                             family C (with FERM domain) member 1
3269 27 CAD61925 28071088                         unnamed protein product
2284 21 XP_141372 28487651 similar to chromosome 20 open reading
                                                                                                      frame 42
 2283 27 AAN75822 25987321                                      URP1
 2280 27 CAC03433 13811938 dJ1056H1.2.1 (novel protein similar to
                                                                      mitogen inducible protein mig-2 (isoform 1))
1906 27 AAH13366 22800409    similar to hypothetical protein MGC10966
 1902 27 BAC04220 21752646 unnamed protein product
 1891 27 AAM19737 30384985 UNC-112 related protein 2 long
                                                                                                 form URP2LF
1498 27 AAH35882 23273527 Unknown (protein for MGC: 46404)
1429 27 BAC03826 21750728 unnamed protein product
826 27 BAA90957 7020004 unnamed protein product
 810 27 BAA91358 7021029 unnamed protein product
 732 27 AAH04347 13279296 Similar to hypothetical protein FLJ20116
 630 21 XP_215844 27732321 similar to chromosome 20 open
                                                                                              reading frame 42
 169 27 BAA82979 20521736 KIAA1027 protein
 169 27 AAD13152 4235275 talin
 169 27 AAH42923 27552808 Unknown (protein for MGC: 45981)
 169 27 AAF23322 6682361 talin
 169 27 AAF27330 6739602 talin
 169 27 NP_006280 16753233 talin 1
 156 27 NP_055874 22035665 talin 2
 156 27 AAM73764 21666571 talin 2
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TABLE 4-2 The top BLAST hits of mig-2 protein in 11 organisms.
      SCORE      P        ACCESSION      GI                N                ORGANISM
       3582 27 AAH17327 16 878257 28 Homo sapiens
       3536 21 AAH33436 23271480 14 Mus musculus
       2254 17 AAH42247 27769222 1 Xenopus laevis
       1706 8 EAA01071 21288778 3 Anopheles gambiae str. PEST
       1637         8 AAF47838 7292434 5 Drosophila melanogaster
       1463         7 CAA99790     3875038 5 Caenorhabditis elegans
       383           21 XP_2195402 7661952 6 Rattus norvegicus
       344           15 CAC44164 14717000 1             Oncorhynchus mykiss
       161           6 AAG25995     10998794 1                  Podocoryne carnea
       102           18 AAN75275     26000436 5 Gallus gallus
       101           3 A57036           1362217 5 Dictyostelium discoideum
Notes: Score—BLAST bits score
            P—Taxonomic node
            Accession—the unique identifier for a sequence record
            GI—“GenInfo Identifier” Sequence identification number
            N—total number of hits in the organism
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ILLUSTRATION 4-5 Alignment of mig-2 protein with its homologies Alignment
among Mig-2 protein in human and its homologies in 4 different species: Mouse or M.
musculus, Sea squid or C. intestinalis, C. elegans and D. melanogaster. Conserved
sequences were found especially at C-terminal and the percentage of similarities of mig-2
to the other 4 species is 97.8%, 47.4%, 47.0% and 51.5% respectively.
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4.2       Mig-2 gene expression in human cancer cell lines
We screened the expression status of mig-2 gene at mRNA level using One-Step RT-
PCR in 7 human cancer cell lines including MCF-7, HT29, Colo205, HCT116, HepG2,
HL60 and Jurkat cells. Mig-2 was expressed widely in all cancer cell lines except HT29
and Colo205, in which mig-2 gene was silenced as shown in Figure 4-1. Thus we chose
HT29 as the cell line in which overexpress mig-2 to explore its functions.
MCF-7, which expresses high level of mig-2 gene (Figure 4-1), was used to extract
mig-2 mRNA and subsequently clone mig-2 gene for the purpose of characterization of
the gene.
4.3      Cloning mig-2
4.3.1    PCR amplification of full-length cDNA of mig-2
Total RNA extracted from MCF-7 cells with a good quality (Figure 4-2) was subjected
to RT. The first strand cDNA was then used for generation of full-length cDNA of mig-2
by PCR. The size of PCR products was approximately 3 kb. As shown in Figure 4-3, the
PCR products were separated on 1% agarose gel and the 3 kb band was removed from the
gel for purification.
4.3.2 Cloning mig-2 into pcDNA3.1 (+)
Mig-2 was incorporated with two restriction cutting sites at two ends: BamH I and
Xho I. The PCR product of mig-2 and the pcDNA 3.1(+) digested by these two enzymes
was subjected to ligation and subsequently transformation. One positive colony was
screened out by PCR using the internal primers of mig-2 as well as restriction enzyme
digestion.
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                                                 MCF-7     HCT116      HT29     Colo205
                         GAPDH
                           MIG-2 
FIGURE 4-1 One-Step RT-PCR of mig-2 expression screening in 4 human cancer
cell lines Mig-2 RNA was detected in MCF-7 and HCT116, but not in HT29 and
Colo205 cells. The housekeeping gene GAPDH was used as control.
                                                       28S
                                                       18S
FIGURE 4-2 Total RNA extracted from MCF-7 cells 2 µl of total RNA was loaded in
1% agarose gel and subjected to electophoresis. The gel photo shows the good quality of
RNA with a strong band of 28sRNA and a half strong band of 18sRNA.
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                                  L        M          M                     L
                                                                  A                                                B
             3kb
FIGURE 4-3 PCR generating of full-length mig-2 cDNA A) L: 1 kb ladder; M: PCR
product of mig-2 cDNA. B) L: 1 kb ladder. The mig-2 PCR products were removed from
the gel for further purification.
69
In the PCR for plasmid screening, the internal primers were used to produce a 480 bp
fragment. As shown in Figure 4-4, a strong band of 480 bp was detected in lane 3,
indicating the possible mig-2 insertion in this clone. In enzyme digestion, EcoR I was
chosen to check the size of construct since there is only one cutting site in the possible
correct construct. As shown in Figure 4-5, the size of the construct is approximately 8.4
kb, i.e. mig-2 (3 kb) plus pcDNA3.1 (+) (5.4 kb).
4.4   Optimizations data
In order to achieve reliable and reproducible results, we performed a series of
optimization for several experimental methods such as MTT, transfection and drug
treatment. The parameters may vary in different experimental systems.
4.4.1 MTT assay
We optimized the initial cell density of HT29 and the duration of MTT incubation. As
shown in Figure 4-6, 4 h incubation with MTT showed a better reading than 1, 2 or 3 h.
Thus 4 h was considered as the optimal duration that a distinctive reading could be
obtained regarding different cell number. Meanwhile we determined the optimal initial
cell number for cytotoxicity assay. As shown in Figure 4-7, the cell number at which the
MTT reading was around 1 was regarded as the optimal cell number i.e. 4000-5000
cells/well.
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                                                     L        1      2       3
                                    500bp
FIGURE 4-4 Plasmid DNA screening by PCR L: 100 bp ladder; lane 1 and lane 2
shows no mig-2 insertion; lane 3 shows a strong band at about 500 bp indicating possible
mig-2 insertion.                                                         
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                                                  L      1       2       3     4      5      6     7
                               8kb
FIGURE 4-5 Plasmid DNA digested by EcoR I L: 1 kb ladder; Lane 1: the mig-2
inserted plasmid DNA with a size of about 8.4 kb; Lane 2-7: negative plasmids without
mig-2 insertion.
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FIGURE 4-6 Optimization of incubation of MTT With an identical number of cells
per well, 4 h incubation with MTT showed the most distinctive difference in MTT
reading, suggesting that 4 h was the optimal duration at which the best reading regarding
cell number can be shown.
FIGURE 4-7 Optimization of cell number We chose the cell number at which MTT




























































Etoposide, 5-FU and staurosporine were used to treat HT29 cells at a range of
concentrations. To compare the sensitivity of HT29 against these three anticancer drugs,
we optimized a range of drug concentrations from the relatively low concentration at
which cells could hardly be killed to the concentration at which approximately 50% of
the cells were killed. As shown in Figure 4-8, the range for etoposide and 5-FU was from
2.5 µM to 40 µM and for staurosporine from 12.5 nM to 200 nM.
4.4.3 Transfection efficiency
We optimized the amount of transfection reagent and the incubation time. The
transfection efficiency was examined under fluorescence microscope. It was found that
using the 6 µl PLUS and 4 µl lipofectamine reagent (suggested starting amount by the
provider) the transfection efficiency in HT29 was very low (about 3%) as shown in
Figure 4-9 A. However, when reduced the PLUS and lipofectamine reagent to 4 µl and
2.5 µl respectively, the efficiency was improved to about 20% (Figure 4-9 B). For the
incubation time, we found that incubating cells overnight did not improve the efficiency
of transfection. Therefore, we set up the optimal transfection conditions as 4 µl PLUS






















































































A                                                                       B
               C
FIGURE 4-8 Optimizations of drug concentrations in HT29 A: Etoposide with a
range from 1 µM to 50 µM; B: 5-FU with a range from 1 µM to 50 µM; C: Staurosporine
with a range from 6.25 nM to 400 nM. The optimal range was chosen from the
concentration of around 10% killing to the concentration of around 70% killing.
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      A                                                   B    A                                             B
FIGURE 4-9 Optimization of transfection efficiency A: Non-optimized transfection
had an efficiency of approximately 3%; B: Optimized transfection with an efficiency of
around 20%.  
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4.5    Sensitivity of mig-2 transfected HT29 cells to different anticancer agents
HT-29, a natural mig-2-null cell line, was transfected with mig-2 construct or empty
vector. Three anticancer reagents: etoposide, 5-FU and staurosporine were used in
cytotoxicity assay. After incubation with drugs at different concentrations for 24 h, the
percentage of viable cells in the two cell lines was measured by MTT.
4.5.1 Drug treatment on transiently transfected HT29
The testing of sensitivity to different anticancer reagents was first performed in
transient transfected HT29 cells. 24 h after transfection of mig-2 construct or empty
vector, cells were exposed to etoposide, 5-FU or staurosporine respectively for 24 h. The
high level of mig-2 mRNA in the transient transfected cells was confirmed by performing
One-Step RT-PCR, as shown in Figure 4-10. The MTT data for the three drugs, however,
showed no significant difference between the two cell lines (Figure 4-11A, B and C).
4.5.2 Establishment of stably transfected HT29
The stably transfected HT29 cells were established and maintained in the medium
with 500 µg/ml Geneticin. The expression of mig-2 gene in the stable cell line was
confirmed using One-Step RT-PCR. Both mig-2 fragment and the neomycin resistance
gene were detectable in the cells (Figure 4-12).
4.5.3 Drug treatment on stably transfected HT29
Stably transfected HT29 cells were seeded in the same density 24 h before drug
treatment. The cells were then cultured in the presence of drugs for 24 h and then
replaced medium with fresh medium and cultured for additional 2 days before subjecting
to the MTT assay. As shown in Figure 4-13, the percentage of variable cells showed no
significant difference between the mig-2 stably transfected cell line and the empty vector
77
transfected cell line. It indicated that mig-2’s expression did not alter the sensitivity of the
cells against these three drugs.
                                                  L           M           P          W
                          500bp                                                                  mig-2
                                                                                                           G3PDH
FIGURE 4-10 Expression of mig-2 detected by One-Step RT-PCR in transient
transfected cells L: 100 bp ladder; M: Mig-2 transfected cells; P: pcDNA3.1 (+)
transfected cells; W: wild type i.e. untransfected cells. The housekeeping gene G3PDH
served as control.
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A                                                                                        B
                                 C
FIGURE 4-11 Sensitivity of transient transfected HT-29 cells to etoposide, 5-FU
and staurosporine The cells were treated with etoposide (A), 5-FU (B) or
staurosporine (C) at a range of concentrations for 24 h. Percentage of viable cells was
measured using ELISA after MTT reaction. Three separate experiments were performed






































































                                              L        M      P                   M        P
                     Neo
      500bp                                                                                 mig-2
                                                                                                      G3PDH
FIGURE 4-12 One-Step RT-PCR to detect mig-2 expression in stably transfected
cells L: 100 bp ladder; M: mig-2 stably transfected cells; P: pcDNA3.1 (+) stably












































































A                                                                                      B
                                      C
FIGURE 4-13 Sensitivity of stably transfected HT-29 cells to etoposide, 5-FU and
staurosporine The cells were treated with etoposide (A), 5-FU (B) or staurosporine (C)
at a range of concentrations for 24 hrs. Percentage of viable cells was measured using
ELISA after MTT reaction. Three separate experiments were performed in triplicate.
Each point represents the average ± SD.   
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4.6    Antiproliferative effect of mig-2
It was observed that stably transfected HT29 cells with mig-2 gene grew in a much
slower rate compared to those transfected with empty vector. The observation was
confirmed by performing two experiments to measure the growth rate of cells: growth
curve determination and colony formation.
4.6.1 Growth curve of stable cell lines
The mig-2 and pcDNA 3.1(+) stably transfected HT29 cell lines were utilized in
growth rate determination. During 10 days culture, HT-29 transfected with mig-2 showed
a much slower growth rate than cells transfected with empty vector (Figure4-14). The
mig-2 stably transfected HT29 showed a doubling time of approximately 24 h. In
contrast, the cells transfected with pcDNA 3.1(+) showed a shorter doubling time of 12 h.
One-Step RT-PCR was used to confirm the expression of mig-2 gene in the cells.
4.6.2 Colony formation
After transfection with mig-2 or empty vector, HT-29 cells were selected by culturing
in medium with 500 µg/ml of Geneticin. HT29 cells transfected with mig-2 showed much
less colonies in number than those transfected with empty vector (Figure4-15). There
were only approximately 6 colonies in mig-2 transfected cells compared to about 80

























                                                                                     *                                      mig-2
                                                                          *                                                 G3PDH
 
                                                                                     *
                                                                         *
FIGURE 4-14 Growth curves of mig-2/plasmid stably transfected HT29 A). Growth
curves of HT29 cells stably transfected with mig2-pcDNA and pcDNA3.1 (+) alone (as
control). The number of viable cells was determined by trypan blue exclusion assay for 7
days consecutively. Data (mean ± SD, n = 6) represent the fold increase in cell number
relative to the originally plated cell number. * P < 0.001. B). Semi-quantitative RT-PCR
determined the expression of mig-2 and neomycin resistant gene (Neo) in cells




















  A                                                                        B
C
FIGURE 4-15 Colony formation assay on mig-2 transfected HT29 cells HT29 cells
were incubated in DMEM with 500 µg/ml of Geneticin for 21 days. A: HT29 transfected
with empty vector. There were approximately 80 colonies formed. B: HT29 transfected
with mig-2. About 6 colonies were observed. C: Similar results were observed from 3
independent cultures, a bar chart was drawn. P value less than 0.01 represented by *.
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4.7   Apoptotic effect of mig-2
In addition to the antiproliferative effect of mig-2 gene transfection to HT 29 cells, we
found that the transient transfection of this gene could also induce apoptosis. This
apoptotic effect has been confirmed using flow cytometry and TUNEL assay.
4.7.1 Flow cytometry
The transiently transfected HT29 cells were subjected to flow cytometry. The
percentage of cell population in every cell phase was showed in the flow cytometry chart.
The percentage of apoptotic cells was demonstrated in the sub-G1 peak. As shown in
Figure 4-16, the percentage of apoptotic cells in mig-2 transfected HT29 was 28.7%,
while in the control cells it was 13.7%.
4.7.2 TUNEL assay
Apoptotic cells triggered by mig-2 gene transfection were also detectable using
TUNEL assay. After transient transfection, HT29 cells were subjected to TUNEL
reaction and then examined under a fluorescence microscope. The apoptotic cells can be
observed with green fluorescence. As shown in Figure 4-17, the cells transfected with
mig-2 showed some distinct green fluoresced cells that were undergoing apoptosis.
However, such cells could barely be observed in the cells transfected with pcDNA3.1 (+).
4.8    Cellular localization of mig-2 protein
To further characterize mig-2 protein, we constructed mig-2 ORF into a plasmid with
a GFP sequence. The constructed plasmid was then used in the transient transfection in
HT29 cells as well as MCF-7 cells. The transfected cells were observed under a
fluorescence microscope. The mig-2-GFP fusion proteins showed distinct green
fluorescence accumulated in the cytoplasm in both HT29 and MCF-7 cells (Figure 4-18),
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Sub-G1   13.7%      A
G1           45.8%
S              12.1%
G2/M       28.4%
Sub-G1   28.7%      B
G1           38.1%
S              10.9%
G2/M       22.3%
compared to the evenly distributed fluorescence in cells transfected with empty vector. It
indicated that mig-2 protein might localize and function in cytoplasm.
FIGURE 4-16 Apoptotic effect of mig-2 gene transfection in HT29 cells assayed by
flow cytometry HT29 cells were transfected with mig-2 or empty vector 48 h before
cells were fixed and stained by PI before analysis. A) HT29 transfected with empty
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FIGURE 4-17 TUNEL assay on the apoptotic effect of mig-2 transfection A ) .
Fluorescent Microscopy showed localized green fluorescence (labeled with fluorescein-
12-dUTP) in the nuclei of the cells transfected with mig-pcDNA (arrows). B). Control





FIGURE 4-18 Intracellular localization of mig-2 protein Transfection of pGFP-
N2/mig-2 resulted in green fluorescence of GFP-mig-2 fusion protein accumulating in
the cytoplasma of HT29 (A) as well as MCF7 (C), compared to the evenly distributed
GFP protein in controlled cells transfected with pGFP-N2 alone (B, D).
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4.9     Expression of mig-2 gene is serum-dependent
As shown in Figure 4-19, after 72 h of serum starvation mig-2 was silenced totally in
HL60 and suppressed significantly in HCT116 cells. 4 h of serum stimulation in HL60
did not re-activate the expression of mig-2 gene. But it elevated the expression level of
mig-2 in HCT116.
4. 10    Down-regulation of mig-2 gene by antisense technology
The down-regulation of mig-2 gene expression using antisense technology was
unsuccessful according to the One-Step RT-PCR results (Figure 4-20). The mRNA level
of mig-2 in the cells did not decrease after the cells were treated with antisense oligos or
with the antisense mig-2 construct. In the established stably transfected HCT116 cells
which express antisense mig-2, the mig-2 expression level was not altered either.
                                            A
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                                          L           AS         A           BS           B
            500bp
                                                                                                                                  mig-2
                                                                                                                                  G3PDH
FIGURE 4-19 Expression of mig-2 is dependent on serum stimulation L: 100 bp
ladder; A: HL60 cells serum starved for 72 h; AS: Starved HL60 with 4 h of serum
stimulation; B: HCT116 cells serum starved for 72 h; BS: Starved HCT116 with 4 h of
serum stimulation. Housekeeping gene G3PDH served as control.   
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                                                    W             L              A           C
                            mig-2
                     G3PDH
FIGURE 4-20 One-Step RT-PCR to detect mig-2 gene expression in antisense
treated cells L: 100 bp ladder; W: untransfected cells; A: cells transfected with antisense
oligo of mig-2; C: cells transfected with control oligo. Housekeeping gene G3PDH
served as control.
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CHAPTER 5    DISCUSSION
In this study, we explored the functional significance of an uncharacterized gene mig-
2 in cell susceptibility against anticancer drugs and in cell growth control in human
cancer cell lines. Based on our data, the expression of mig-2 gene in HT29 colon cancer
cells inhibited cell proliferation and induced apoptosis. However, the overexpression of
mig-2 in HT29 did not enhance the cell sensitivity to etoposide, 5-FU or staurosporine.
Mig-2 protein was localized in cytoplasm according to the observation of mig-2-GFP
fusion protein. In addition, the expression of mig-2 gene was serum-dependent.
Our hypothesis that mig-2 gene could be able to confer cell susceptibility to anticancer
drugs was mainly based on the high homology (60%) between mig-2 and the novel gene
we identified in mouse (Shen et al., 1999), which was able to enhance the sensitivity of
murine tumor cells against a panel of anticancer drugs. Our data, however, was not
supporting the hypothesis. We thus concluded that mig-2 gene in human, though
possessing the homology with the novel gene in mouse, might not share the similar
function in reversing anticancer drug resistance.
In the present study, we revealed that expression of mig-2 gene had antiproliferative
effect on HT-29. This finding again disagreed with our previous anticipation that mig-2
might stimulate cell proliferation and subsequently enhance susceptibility of the cancer
cells to cytotoxic agents. However, these two unexpected results, to some extent, were
not contradictory to each other. Additionally, we found that overexpression of mig-2 in
HT29 induced apoptosis, which was in agreement with the antiproliferative effect.
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Although our experimental results were not consistent with the initial hypothesis, they
indeed demonstrated that mig-2 was involved in the cell growth control by inhibiting cell
proliferation and inducing apoptosis in HT29 cells. The cell growth control is considered
to be the key mechanism to understand and finally overcome the carcinogenesis. Various
biological signaling pathways regarding proliferation, apoptosis, cell adhesion, cytokine
production, etc. are tightly involved into this process. Possible pathways in which mig-2
gene may be involved are discussed below.
According to recent studies on as well as the identification process of mig-2, we found
that two possible pathways could be used to explain mig-2’s involvement in cell growth
control. One is the integrin-mediated cell growth control in which integrins act as the
bridge between the ECM and many cytoplasmic proteins to regulate cell survival,
proliferation, differentiation and migration.  The other is the mitogen-mediated cell
growth control in which various growth factors stimulate cell proliferation by binding
with specific receptors and thus activate various downstream signal transduction
cascades. The patterns of these two mechanisms may be very different, but the two
pathways do not function independently. It is noted that an extensive crosstalk takes place
between each other.
A recent study revealed that mig-2 was a component of adhesion complexes where
cell attach to the ECM (Tu et al., 2003). They also indicated in their study that mig-2 was
able to coupled to ILK both physically and functionally and consequently integrins in
mammalian cells. ILK, a Serine/Threonine kinase, mediates a diversity of functions
relating to its role in coupling integrins and growth factor receptors to downstream
signaling pathways. ILK mediates the transduction of signals from ECM components to
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intracellular proteins via integrins. It has been shown that overexpression of ILK in
epithelial cells leads to anchorage-independent cell growth, cell cycle progression, and
constitutive up-regulation of cyclin D and cyclin A expression (Radeva et al., 1997).
As we found that expression of mig-2 in HT29 cells inhibited cell growth, we
predicted that mig-2 might exert its antiproliferative effect through interacting with ILK,
consequently integrin mediated signaling pathway. Clearly, future studies on the
interactions between mig-2 and integrins are required to test the mechanism lying behind
the antiproliferative effect.
Mig-2 gene was identified in the progression of G0S phase in quiescent fibroblasts
upon serum stimuli. Our experimental data demonstrated that the expression of mig-2
gene was serum dependent in HCT116 and HL60 cells. This observation, along with the
identification process of mig-2 indicated the possible involvement of mig-2 gene in the
mitogenic signaling pathway.
It was unexpected to us that mig-2 gene which was induced to express upon mitogenic
stimuli, instead of stimulating cell proliferation, inhibited cell growth. Many IE mitogen
inducible genes have been defined as protooncogenes whose expression can transform
cells to unlimited growth, such as c-Myc (Kaczmarek et al., 1985) and c-Fos (Müller et
al., 1984). As an IE gene in the mitogen-mediated signal transduction, mig-2 appeared
unique among the group by inhibiting cell growth.
It is likely that mig-2 may play a role in inhibiting cell cycle progression by ultimately
interrupting cyclin D induction, which is the key event in various mitogenic signaling
pathways (Matsushime et al., 1991). Mig-2 might be involved somewhere in certain
known pathway. However, it is very possible that mig-2 lies in an uncharacterized
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pathway since no known signal molecule to date has been found related to mig-2.
Certainly further investigations are needed to identify the mechanism underlying the
antiproliferative effect of mig-2 gene.  
In addition to the antiproliferative effect, we demonstrated that expression of mig-2
gene induced apoptosis in transient transfected HT29 cells. This apoptotic effect was
considered consistent with the antiproliferative effect in the mig-2 overexpressed stable
cell line that showed reduced growth rate. As we know, various molecules are involved in
the process of apoptosis. But there is no known molecule identified to date associated
with mig-2 gene. Again the mechanism of mig-2’s apoptotic effect needs further
exploration. Here we discuss a likely mechanism of the apoptotic effect of mig-2.
Obviously, many other possible mechanisms exist. And the potential significance of mig-
2 gene is prominent.
The observation in recent study of mig-2 coupling with ILK physically and
functionally indicates that ILK or integrin may play a role in apoptotic effect of mig-2
gene. This apoptosis induced by mig-2 in HT29 cells is possibly associated with
detachment-induced apoptosis, so called anoikis (Meredith et al., 1993; Frisch and
Francis, 1994), in which cells undergo apoptosis due to loss of cell anchorage. The
anchorage of cells to the ECM is mainly mediated by the transmembrane receptors
integrins. It has been found that integrins mediate cell matrix adhesion and regulate cell
growth and survival in human colon cancer cell lines (Buda et al., 2003; O’Brien et al.,
1996). However, overexpressing mig-2 in the cells did not cause any changes in
morphology or anchorage based on our observation under microscopy. It was possible
that the interruption of cell anchorage happened without obvious changes of cell
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morphology, especially in the very early stage. Thus a more sensitive experimental
method is suggested to test the possibility of anoikis induced by mig-2.   
Based on our observation, mig-2 protein was located in cytoplasm in both HT29 and
MCF7 cells. Characterization of the proteins encoded by IE genes in mitogen signaling
transduction has already discovered a number of regulatory molecules. Particular interest
lies in those nuclear proteins, and many of them have been identified as transcription
factors. Mig-2 belonged to the IE gene, but it encodes a cytoplasmic protein. This finding
was not supporting the prediction that mig-2 could probably be a nuclear transcription
factor triggered in the mitogenic stimuli.
Considering the functions of mig-2 in cell growth control that we have revealed in our
study, it is likely that mig-2 protein functions as a signal molecule in the cytoplasm.
Upon the activation of the transmembrane receptor, for example integrin, mig-2 might be
recruited into certain pathway in inhibiting cell proliferation as well as executing
apoptosis.
Tu et al. demonstrated that mig-2 protein, as a component of cell-matrix adhesion
complex, was indispensable for proper control of cell shape change (Tu et al., 2003).
However, we demonstrated that expression of mig-2 gene varies in different cancer cell
lines. Especially in some cell lines such as HT29 and Colo205 it was totally silenced. As
we know, HT29 is an attached cell line that needs anchorage and shape modulation for
cell survival and growth. In contrast, some suspension cell lines, for example Jurkart cell
line, express mig-2 gene in a high level (data not shown). These findings indicate that
mig-2 might not play the same role of cell shape modulation in all the cell lines. Instead
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the functions of mig-2 gene could be variable depending on cell types. Indeed, we
showed mig-2 played a role in cell growth control in HT29.
Two homologues of mig-2, URP1 and Kindlin-1, have been identified and
characterized recently. The very distinctive identification processes as well as functions
of these two genes were described respectively. The various functions of mig-2
homologues further indicate multiple biological roles that mig-2 may exert regarding
different types of cells and tissues.   
The wide range of hits (totally 74 hits in 11 organisms including 28 hits in human
beings) of mig-2 protein in BLink search indicated that various roles mig-2 gene could
play in cell behavior. Although most of the corresponding homologues of mig-2 gene in
other organisms have not yet been characterized, some of them could help to figure out
the potential significances of mig-2 gene in human. For example the C. elegans ortholog
of mig-2, UNC112, has been intensively characterized as a membrane associated protein
in adhesion complex. The two homologues of mig-2, URP1 and URP2, which were
identified in human recently, were both reported being associated with UNC-112. Clearly
characterization of mig-2 homologues in human as well as in other organisms will help
clarify the functions of mig-2 gene.
Although there are plenty of evidence showing mig-2 involving cytoskeleton linking
such as the homology with talin and filopodin, and the PH and FERM domain containing,
it is insufficient to say that mig-2 only functions as a cytoskeleton linker.  PH domain is
thought a feature of both cytoskeleton-associated molecules and cell signaling molecules.
Based on our experimental results, it is very likely that mig-2 functions as a signaling
molecule in cell growth control.
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In addition, four homologous proteins of mig-2 in various organisms were aligned
with human mig-2. The highly conserved amino acid sequences at C-terminal indicated
the potential significance of the C-terminal of mig-2 protein.
The failure of suppressing mig-2 gene by antisense technology in our study might due
to various reasons. It has been shown that the successful use of antisense oligonucleotides
to suppress gene expression is somewhat limited since only a small portion of all possible
antisense sequence against a given target sequence shows efficacy in the respective test
system (Peyman et al., 1995; Monia et al., 1996). The effectiveness of antisense
oligonucleotides is strongly dependent on local target RNA structure, on chemical
properties and sequences of the oligos, and on the characteristics of the biological system
and the gene product, respectively (Far et al., 2001). Although the reasons could be
complicated, the relative large mig-2 mRNA (more than 3 kb) was likely one of them. A
complex secondary structure may exit in mig-2 mRNA since the current level of
sophistication of the algorithms for RNA 2D structure prediction is not sufficient for
accurately analyzing long mRNA (Toschi, 2000).
The antisense plasmid was generated by subcloning partial of mig-2 gene in antisense
orientation under a chosen plasmid. Antisense mRNA was then expressed and competed
with the target mRNA for translation. The advantage of antisense plasmid is that it can
introduce a much longer antisense mRNA than antisense oligos. Currently limitations,
however, are low efficiency of gene transfer and poor long-term expression. In order to
overcome these limitations, we generated stable cell line. The mig-2 gene, however, was
still not suppressed. It indicated that mig-2 gene might be somehow resistant to the
antisense RNA.
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In addition, our antisense study was also limited by our detection method for the
effects of antisense technology. Because mig-2 is an uncharacterized gene, the antibody
is not commercially available in this stage of study. We detected the expression level of
the gene only at mRNA level. Antisense oligos have several potential sites of action.
They can inhibit translation by hybridizing to the specific mRNA and the hybridization
prevents either ribosomal assembly or ribosomal sliding along mRNA. This type of
action assumes that antisense are acting in the cytosol and do not alter measurable mRNA
levels (Simon, 1988). Indeed, there are several studies reporting antisense effects without
detectable change in target mRNA levels (Wahlestedt et al., 1993). Therefore, mig-2
protein detection is needed in our further study to confirm the suppression of mig-2 gene
by antisense technology.
Recently the rapid development of small-interfering RNAs (siRNAs) has provided
researchers a novel and powerful tool to silence gene expression since its discovery in
2001 (Elbashir et al., 2001). siRNAs are mediators in the RNA interference pathway
triggered by double-stranded RNA (dsRNA). Basically the Dicer cleaves long dsRNA
into 21- to 23-nt small duplex RNA that trigger sequence specific gene silencing in
mammalian somatic cells without activation of the unspecific interferon response.
Numerous publications have firmly established the efficacy of siRNA in specific gene
suppression. Especially in one recent study on mig-2, it was shown that mig-2 was
successfully silenced by synthesized siRNA in human fibroblast cells WI-38 and mouse
C2C12 cells (Tu et al., 2003).
We carried out a functional exploration on an uncharacterized gene: mig-2, especially
in the fields of anticancer drug resistance and the cell growth control. We have tested our
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hypothesis and demonstrated that mig-2 did not enhance cell sensitivity to anticancer
drugs in human cancer cells. In addition, we have found that overexpression of mig-2
gene in HT29 inhibited cell growth and triggered apoptosis. This finding, unexpected as
it was, supported our preliminary prediction that mig-2 gene was involved in cell growth
control. Additionally, we demonstrated that mig-2 protein was accumulating in cytoplasm
and its expression was serum-dependent.
Because our hypothesis that mig-2 enhances cell sensitivity to anticancer drugs was
mainly based on the similarity of its sequence with the unpublished sequence of a novel
gene that was identified in mouse and was proven capable of reversing the acquired drug
resistance. Furthermore, mig-2 has been left uncharacterized for a long time since its
identification in 1994, indicating the originality of this study.
Our findings contributed to the understanding of mig-2 gene’s functions and revealed
its potential significance in carcinogenesis. Although there are some recent publications
related to mig-2 gene, none of them explored the field in which we studied about mig-2.
Instead they showed that mig-2 functions in cell-matrix adhesion and subsequently cell
shape modulation.
However as a pilot and novel study, our exploration was restricted due to limited
information and resources of mig-2 gene. Firstly, most of our work was limited at RNA
level because mig-2 antibody was unavailable. Therefore the events in translation from
RNA to protein or the mig-2 protein status in different cell lines were unable to know.
Secondly, all our study at this stage was performed in limited number of human cancer
cell line. Clearly the results need to be tested in more cell lines including both cancer cell
lines and normal cell lines. Thirdly, the study was totally in vitro, and surely test in vivo
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is required in the future. Lastly, our study at this stage was limited in exploring functions
of mig-2. However the mechanisms or pathways behind these functions, which are far
more important in the understanding of mig-2’s functions, have not yet been explored. It
is also demanding to explore the possible pathways in which mig-2 gene may be
involved, since little information can be found regarding to mig-2 gene.
Our present study has demonstrated the significance of mig-2 gene in cancer cell
growth control, future work on exploration and characterization of mig-2 is needed and of
great interest.
A) in vivo study. The present work was mainly carried out in human cancer cell
lines i.e. in vitro. Thus a further test on mig-2 in in vivo condition should be
done. A simple animal model such as nude mice can be used firstly for the
injection and tumor formation of mig-2 stably transfected cells.
B) Protein level study. To facilitate the experiments at protein level, a mig-2
antibody (either monoclonal or polyclonal) need to be generated. Then the
mig-2 protein level can be detected in various cell lines including the stably
transfected cell lines.
C) Pathway exploration. ILK and integrin mediated pathway are suggested to
explore based on the recent studies on mig-2. However a comprehensive
method to detect proteins interaction is necessary considering the complicated
roles mig-2 may play in cell behavior.
D) Suppression of mig-2. It is important to explore mig-2 gene’s functions and
underlying mechanisms in two ways i.e. gain of function and loss of function.
Although the failure of antisense in our study, it is still worthy to seek an
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effective way to suppress the gene. One is to continue using antisense oligos
but design the oligos corresponding to different locations on mig-2 mRNA.
The other is to design siRNA for mig-2 gene silencing. Because Tu et al has
shown the successful suppression of mig-2 by siRNA in their study (Tu et al.,
2003), it is a highly suggestive method in the future exploration of mig-2
gene’s functions.
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CHAPTER 6    CONCLUSIONS
Mig-2, as an uncharacterized gene, showed possible involvements in cancer cell
susceptibility to anticancer drugs as well as in cell growth control. Our data showed that
expression of mig-2 in HT29 colon cancer cells inhibited cell proliferation, induced
apoptosis, but did not enhance cell sensitivity to anticancer reagents. The colony
formation and growth curve determination confirmed the growth inhibitory effect of mig-
2 gene. The apoptosis was determined by flow cytometry and TUNEL. Cytotoxic assay
demonstrated no significant enhancement of cell susceptibility to anticancer drugs
etoposide, 5FU or staurosporine after transfection of mig-2 in HT29. The identification
process and the recent studies on mig-2 shed light on the molecular mechanism of mig-
2’s functions. We concluded that mig-2 gene might play an important role in the
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